INFECTIONS.

This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections, like HBV or HCV.

The present invention relates to the use of pyrimidine derivatives in the treatment of viral infections, immune or inflammatory disorders, whereby the modulation, or agonism, of toll-like-receptors (TLRs) is involved. Toll-Like Receptors are primary transmembrane proteins characterized by an extracellular leucine rich domain and a cytoplasmic extension that contains a conserved region. The innate immune system can recognize pathogen- associated molecular patterns via these TLRs expressed on the cell surface of certain types of immune cells. Recognition of foreign pathogens activates the production of cytokines and upregulation of co-stimulatory molecules on phagocytes. This leads to the modulation of T cell behaviour.

It has been estimated that most mammalian species have between ten and fifteen types of Toll-like receptors. Thirteen TLRs (named TLR1 to TLR13) have been identified in humans and mice together, and equivalent forms of many of these have been found in other mammalian species. However, equivalents of certain TLR found in humans are not present in all mammals. For example, a gene coding for a protein analogous to TLR10 in humans is present in mice, but appears to have been damaged at some point in the past by a retrovirus. On the other hand, mice express TLRs 1 1 , 12, and 13, none of which are represented in humans. Other mammals may express TLRs which are not found in humans. Other non-mammalian species may have TLRs distinct from mammals, as demonstrated by TLR14, which is found in the Takifugu pufferfish. This may complicate the process of using experimental animals as models of human innate immunity.

For detailed reviews on toll-like receptors see the following journal articles. Hoffmann, J.A., Nature, 426, p33-38, 2003; Akira, S., Takeda, K., and Kaisho, T., Annual Rev. Immunology, 21 , p335-376, 2003; Ulevitch, R. J., Nature Reviews: Immunology, 4, p512-520, 2004.

Compounds indicating activity on Toll-Like receptors have been previously described such as purine derivatives in WO 2006/1 17670, adenine derivatives in WO 98/01448 and WO 99/28321 , and pyrimidines in WO 2009/067081 . However, there exists a strong need for novel Toll-Like receptor modulators having preferred selectivity, higher potency, higher metabolic stability, and an improved safety profile compared to the compounds of the prior art. In the treatment of certain viral infections, regular injections of interferon (IFNa) can be administered, as is the case for hepatitis C virus (HCV), (Fried et. al. Peginterferon-alfa plus ribavirin for chronic hepatitis C virus infection, N Engl J Med 2002; 347: 975-82). Orally available small molecule IFN inducers offer the potential advantages of reduced immunogenicity and convenience of administration. Thus, novel IFN inducers are potentially effective new class of drugs for treating virus infections. For an example in the literature of a small molecule IFN inducer having antiviral effect see De Clercq, E.; Descamps, J.; De Somer, P. Science 1978, 200, 563-565. IFNa is also given in combination with other drugs in the treatment of certain types of cancer (Eur. J. Cancer 46, 2849-57, and Cancer Res. 1992, 52, 1056 ). TLR 7/8 agonists are also of interest as vaccine adjuvants because of their ability to induce pronounced Th1 response (Hum. Vaccines 2010, 6, 1 -14; Hum. Vaccines 2009, 5, 381 -394).

In accordance with the present invention a compound of formula (I) is provided

or a pharmaceutically acceptable salt, tautomer(s), solvate or polymorph thereof, wherein

Ri is hydrogen, methyl. Ci- ₂ alkyl, cyclopropyl, methoxy, halogen, hydroxyl, trifluoromethyl, or difluoromethyl,

R ₂ is Ci-salkyl, (Ci-4)alkoxy-(Ci- ₄ )alkyl, C3- ₇ cycloalkyl, C _4-7 heterocycle, aromatic, bicyclic heterocycle, arylalkyl, heteroaryl, heteroarylalkyl each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, amino, Ci-ealkyl, di-(Ci-6)alkylamino, Ci- ₆ alkylamino, Ci-ealkyl, C-i-6 alkoxy, C3-6 cycloalkyl, carboxylic acid, carboxylic ester, carboxylic amide, heterocycle, aryl, alkenyl, alkynyl, arylalkyl, heteroaryl, heteroarylalkyl, nitrile, and

R ₃ is C _4- 8alkyl, C ₄ -8alkoxy, C2-6 alkenyl or C^alkynyl, each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, amino, Ci-3alkyl, Ci-3alkoxy or C3-6 cycloalkyl, nitrile.

In a first embodiment the present invention provides compounds of formula (I) wherein R ₃ is butyl or pentyl and wherein R ₂ and Ri are as specified above.

In a further embodiment the invention concerns compounds of formula (I) wherein R ₃ is C _4- 8alkyl substituted with hydroxyl, and wherein R ₂ and Ri are as specified above.

Another embodiment relates to compounds of formula (I) wherein R ₃ , when being C ₄ -salkyl substituted with hydroxyl, is one of the following

Furthermore the present invention also provides compounds of formula (I) wherein Ri is hydrogen or -CH ₃ and wherein R ₂ and R ₃ are as specified above.

In another embodiment the present invention provides compounds of formula (I) wherein wherein R ₂ is arylalkyl or heteroarylalkyl, substituted with Ci _-3 alkyl, hydroxyl, alkoxy, nitrile, heterocycle or ester and wherein Ri and R ₃ are as specified above. In a further embodiment the current invention concerns compounds of formula (I) wherein R ₂ is Ci _-3 alkyl substituted by aryl, heterocycle, or heteroaryl which is further substituted by Ci _-3 alkyl, alkoxy, carboxylic ester or carboxylic amide and wherein Ri and R ₃ are as specified above

Furthermore the invention relates to compounds of formula (I) wherein R ₂ is one of the following examples that can be further substituted with Ci _-3 alkyl, hydroxyl, alkoxy, nitrile, heterocycle or ester.

The preferred compounds according to the invention are:

The compounds of formula (I) and their pharmaceutically acceptable salt, tautomer(s), solvate or polymorph thereof have activity as pharmaceuticals, in particular as modulators of Toll-Like Receptors (especially TLR7 and/or TLR8) activity. In a further aspect the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Furthermore a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to the current invention, or a pharmaceutical composition comprising said compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof can be used as a medicament.

Another aspect of the invention is that a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, or said pharmaceutical composition comprising said compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof can be used accordingly in the treatment of a disorder or disease in which the modulation of TLR7 and /or TLR8 is involved. The term "alkyl" refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon containing the specified number of carbon atoms.

The term "halogen" refers to fluorine, chlorine, bromine or iodine. The term "alkenyl" refers to an alkyl as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond.

The term " alkynyl" refers to an alkyl as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond. The term "cycloalkyl" refers to a carbocyclic ring containing the specified number of carbon atoms.

The term "heteroaryl" means an aromatic ring structure as defined for the term "aryl" comprising at least 1 heteroatom selected from N, 0 and S, in particular from N and 0. The term "aryl" means an aromatic ring structure optionally comprising one or two heteroatoms selected from N, 0 and S, in particular from N and 0. Said aromatic ring structure may have 4, 5, 6 or 7 ring atoms. In particular, said aromatic ring structure may have 5 or 6 ring atoms.

The term "bicyclic heterocycle" means an aromatic ring structure, as defined for the term "aryl" comprised of two fused aromatic rings. Each ring is optionally comprised of heteroatoms selected from N, 0 and S, in particular from N and 0.

The term arylalkyl" means an aromatic ring structure as defined for the term "aryl" optionally substituted with an alkyl group. The term "heteroarylalkyl" means an aromatic ring structure as defined for the term "heteroaryl" optionally substituted by an alkyl group.

The term "alkoxy" refers to an alkyl (carbon and hydrogen chain) group singular bonded to oxygen like for instance a methoxy group or ethoxy group.

Heterocycle refers to molecules that are saturated or partially saturated and include ethyloxide, tetrahydrofuran, dioxane or other cyclic ethers. Heterocycles containing nitrogen include, for example azetidine, morpholine, piperidine, piperazine, pyrrolidine, and the like. Other heterocycles include, for example, thiomorpholine, dioxolinyl, and cyclic sulfones.

Heteroaryl groups are heterocyclic groups which are aromatic in nature. These are monocyclic, bicyclic, or polycyclic containing one or more heteroatoms selected from N, O or S. Heteroaryl groups can be, for example, imidazolyl, isoxazolyl, furyl, oxazolyl, pyrrolyl, pyridonyl, pyridyl, pyridazinyl, or pyrazinyl. Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Suitable base salts are formed from bases which form non-toxic salts. The compounds of the invention may also exist in unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.

The term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal structure.

The compounds of the present invention may be administered as crystalline or amorphous products. They may be obtained for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient depends largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral, rectal, or percutaneous administration. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations that can be converted, shortly before use, to liquid forms. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

Those of skill in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub- doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form. The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective amount ranges mentioned above are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.

Preparation of compounds.

Compounds of formula (I), where Ri is hydrogen atom are prepared according to scheme 1.

A B

°

Scheme 1

Compounds of type A, in scheme 1 are made by either

(i) Reaction of a heterocyclic alcohol with a halogenated ester and an suitable base, for example potassium carbonate, cesium carbonate, or sodium hydride. Example shown in scheme 2a.

(ii) Reaction of an alcohol, or hydroxy ester, for example 2-hydroxy ethyl acetate, with an alkyl halide using an appropriate base, for example sodium hydride. Example shown in scheme 2b.

Scheme 2b

Compounds of formula (I), when Ri is alkyl, cycloalkyl, trifluoromethyl, or alkoxy and where R ₂ is aryl or heteroaryl, are prepared as in scheme 3 below. The betaketoester (E) can be chlorinated using, for example, thionyl chloride to provide the 2-chloro-beta-ketoester intermediate (F). The phenol or hetero- aromatic alcohol (R2OH) is combined with an equimolar ratio of aqueous sodium hydroxide. The solvents are then removed under reduced pressure to afford the phenol or heteroaromatic alcohol salt of R2. This salt is combined with the 2-chloro- -ketoester intermediate (F) to afford intermediate G according to literature procedure. Intermediate G is then combined, with or without base, with guanidine carbonate in an appropriate solvent, for example, ethanol. Intermediate H is then reacted with phosphorous oxychloride to form the chloropyrimidine intermediate (J). The products are then formed as a result of heating (J) in the presence of excess amine and optionally excess organic base, for example triethylamine, at elevated temperature. This is a general scheme using methods known to a skilled person, see for instance Organic Syntheses volume 33, p.43 (1953).

Compounds

Scheme 3

Compounds

J

Scheme 4

Compounds of formula (I), when Ri is alkyl, cycloalkyi, trifluoromethyl, or alkoxy and where R ₂ is aromatic or aliphatic, can be prepared according scheme 4. This reaction scheme begins with a crossed-Claisen reaction where an acyl chloride reacts with ester intermediate A ( shown in scheme 1 ) to form intermediates (G) as in scheme 3. From intermediate G, the reaction scheme follows the same pathway to the products as in scheme 3. This is a general scheme using methods known to a skilled person, see for instance The Journal of American Chemical Society volume 127, page 2854 (2005).

Experimental Section.

Synthesis of Intermediate A-1.

A-1

To a mixture of ethyl glycolate [623-50-7] (250.00 g, 2.40 mol), NaH (105.65 g, 2.64 mol), tetrabutylammonium iodide (TBAI) (88.70 g, 240.14 mmol) in anhydrous THF (2 L) was added benzyl bromide (451 .80 g, 2.64 mol) dropwise at 0°C. The resulting mixture was stirred at 25°C for 16 hours. The reaction mixture was quenched with saturated, aqueous ammonium chloride (1 L), and the aqueous layer was extracted with ethyl acetate (3 x 1 L). The combined organic layers were washed with brine (1 L), dried over magnesium sulfate, the solids were removed via filtration, and the solvents of the filtrate were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 6: 1 ) to obtain intermediate A-1 (200 g).

¹ H NMR (CDCIs 400MHz) δ ppm 7.37-7.27 (m, 5H); 4.62 (s, 2H), 4.24-4.19 (q, J = 6.8 Hz, 2H); 4.07 (s, 2H); 1.29-1 .25 (t, J = 6.8 Hz, 3H).

Procedure for preparation of Intermediate B-1.

A-1 B-1

To a stirred suspension of NaH (45.30 g, 1.13 mol) in anhydrous THF (1 .2 L) was added ethyl formate (114.42 g, 1 .54 mol). The suspension was cooled in an ice bath, and then compound A-1 (200 g, 1 .03 mol) in anhydrous THF (300 ml_) was added dropwise via an addition funnel. The white mixture was stirred at 0°C to room temperature for 5 hours. During this time, the reaction was exothermic and turned yellow. In a separate flask, guanidine carbonate [593-85-1 ] (111 .31 g, 0.618 mol) was treated with a sodium ethoxide solution, freshly prepared by the careful addition of Na (28.41 g, 1 .24 mol) to anhydrous ethanol (750 mL) at room temperature. The off-white slurry obtained after stirring for 1 hour, was then added to the yellow solution prepared above. The resulting pale yellow reaction mixture was heated to reflux for 15 hours. The solvent was removed, and then the crude residue was dissolved in water (1 .5 L). The mixture was adjusted to pH=5 with acetic acid. The solid was collected, washed extensively with water and ethanol to give intermediate B-1 (160 g).

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 4.90 (s, 2 H), 6.33 (br. s., 2 H), 7.25 (s, 1 H), 7.29 - 7.42 (m, 5 H), 1 1 .21 (br. s., 1 H)

Procedure for preparation of intermediate C-1. Reaction Scheme:

B-1 C-1 A suspension of intermediate B-1 (160 g, 0.74 mol) in POCI3 (900 mL) was heated to 100°C under N ₂ with stirring for 5 hours. The reaction mixture was cooled to room temperature. The excess POCI3 was removed under reduced pressure, the oil residue was poured into cold, sat. aq. NaHC0 ₃ (2 L) that was stirred for 30 minutes. The mixture was extracted with ethyl acetate (3 x 1 .5 L). The combined organic layers were separated and washed with brine (1 L), dried over sodium sulfate, the solids were removed via filtration, and the solvents of the filtrate were concentrated to afford intermediate C-1 (70 g) as a yellow solid. The product was used in the next step without further purification.

Procedure for preparation of compound 1.

C-1 To a suspension of C-1 (70.00 g, 297.03 mmol) in ethanol (1 .4 L) was added n- butylamine (217.24 g, 2.97 mol) and triethylamine (60.1 1 g, 594.05 mmol). The reaction mixture was heated to reflux for 16 hours. The reaction mixture was cooled to room temperature and the solvents were removed under reduced pressure. The residue was purified by silica gel flash chromatography using a petroleum ether to ethyl acetate gradient to obtain 1 (26 g) as a pale yellow solid.

¹ H NMR (400 MHz, METHANOL-^) δ ppm 0.96 (t, J=7.3 Hz, 3 H), 1 .32 - 1 .43 (m, 2 H), 1 .52 - 1 .61 (m, 2 H), 3.38 (t, J=7.2 Hz, 2 H), 5.01 (s, 2 H), 7.28 (s, 1 H), 7.31 - 7.46 (m, 5 H)

1 D-1

Preparation of intermediate D-1.

Into a 100 mL round bottom flask equipped with a magnetic stir bar was placed 1 (1 g, 3.67 mmol) in acetic anhydride (40 mL). The yellow solution was allowed to stir at reflux for 15 hours. The solvents were removed under reduced pressure. The crude was purified via silica gel chromatography using a heptane to ethyl acetate gradient. The best fractions were collected and the solvents were removed under reduced pressure to afford a white solid, D-1. LC-MS: Anal. Calcd. For C19H24N4O3: 356.19; found 357[M+H] ⁺

¹ H NMR (400 MHz, CHLOROFORM-cf) δ ppm 0.94 (t, J=7.4 Hz, 3 H), 1 .31 - 1 .45 (m, 2 H), 1 .50 - 1 .67 (m, 2 H), 2.31 (s, 6 H), 3.44 (m, J=6.0 Hz, 2 H), 5.12 (s, 2 H), 5.41 - 5.52 (m, 1 H), 7.43 (m, J=1 .5 Hz, 5 H), 7.79 (s, 1 H) Preparation of intermediate D-2.

D-1 D-2

Method A. Into a 250 ml_ erlenmeyer flask equipped with a magnetic stir bar was placed intermediate D-1 (1 g), and ethanol (100 ml_). The flask is sparged with nitrogen, followed by the addition of 10% Pd on carbon (100 mg). The flask was sealed and the atmosphere removed and replaced with hydrogen. The reaction was allowed to stir at room temperature for 15 hours. The heterogeneous mixture was filtered through packed celite and the solvents of the filtrate were removed under reduced pressure to afford D-2 in quantitative yield.

Method B. A 0.1 M solution of starting material in methanol was run through the H-cube, equipped with a 10% Pd/C cartridge, at 0.5 mL/min and 30 bar pressure of hydrogen. LC-MS shows complete conversion. The solvents were removed under reduced pressure. The crude was purified via silica gel chromatography using a dichloromethane to 10% methanol in dichloromethane gradient. The best fractions were pooled; the solvents were removed under reduced pressure to afford a white solid, D-2.

LC-MS: Anal. Calcd. For C12H18N4O3: 266.14; found 267[M+H] ⁺

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.87 (t, J=7.4 Hz, 3 H), 1 .28 (dd, J=14.9, 7.4 Hz, 2 H), 1 .49 (t, J=7.2 Hz, 2 H), 2.15 (s, 6 H), 3.20 - 3.37 (m, 2 H), 7.02 - 7.12 (m, 1 H), 7.58 (s, 1 H), 10.27 (br. s, 1 H)

Preparation of intermediate D-3.

Into a 100 mL round bottom flask was placed 1 (1 g, 3.67 mmol), di-fe/f-butyl dicarbonate (7.5 g), and acetonitrile (50 mL). The yellow solution was stirred at reflux for 16 hours. The solvents were removed under reduced pressure. The residue was purified via silica chromatography using a prepacked 80g silica column and a heptane to ethyl acetate gradient autocollecting at 254nm. The best fractions were pooled to afford a yellow oil, D-3.

LC-MS: Anal. Calcd. For C25H36N4O5: 472.269; found 473[M+H] ^{+ 1} H NMR (400 MHz, CHLOROFORM-cf) δ ppm 0.94 (t, J=7.4 Hz, 3 H), 1 .33 - 1 .42 (m, 2 H), 1 .46 (s, 18 H), 1 .50 - 1 .65 (m, 2 H), 3.35 - 3.51 (m, 2 H), 5.09 (s, 2 H), 5.31 - 5.38 (m, 1 H), 7.36 - 7.48 (m, 5 H), 7.75 (s, 1 H)

Preparation of intermediate D-4.

Intermediate D-4 is prepared according to the procedure to prepare intermediate D-2, employing either method A or B.

LC-MS: Anal. Calcd. For C18H30N4O5: 382.222; found 383[M+H] ⁺

1H NMR (400 MHz, CHLOROFORM-cf) δ ppm 0.95 (t, J=7.3 Hz, 3 H), 1 .39 (s, 18 H), 1 .40 - 1 .45 (m, 2 H), 1 .53 - 1 .64 (m, 2 H), 3.42 - 3.51 (m, 2 H), 5.66 (s, 1 H), 7.43 (s, 1 H) Preparation of compound 2.

D-4

Into a 30 ml_ vial was placed intermediate D-4 (200 mg, 0.52 mmol), DMF (5 ml_), 1 -(3-bromopropyl)-4-methoxybenzene (130 mg, 0.57 mmol), and cesium carbonate (508 mg, 1 .56 mmol). The reaction was allowed to stir for 15 hours at room temperature. The solids were removed via filtration. The solvents of the filtrate were removed under reduced pressure and the crude was reconstituted in methanol and to it was added HCI (6M in isopropanol) and the reaction was allowed to stir 15 hours at room temperature. The solvents were removed under reduced pressure and the crude was purified via reverse phase separation to afford 2 as the free base.

Preparation of intermediate G-1. TiCI ₄ , Bu ₃ N,1 -methylimidazole

A-1 G-1

To a stirred solution of A-1 (60 g, 309 mmol, 1 eq) and 1 -methylimidazole (30.4 g, 370 mmol, 1 .2 eq) in CH ₂ CI ₂ (1 L) was added acetyl chloride (24.3 g, 309 mmol, 1 eq) at -45 °C under N ₂ . After stirring for 20 min, TiCI ₄ (210 g, 1 .08 mol, 3.5 eq) and tributylamine (230 g, 1 .24 mol, 4 eq) were added to the mixture at -45°C under N ₂ , and continues to stir for 50 minutes at -45°C under N ₂ . After completion, water and ethyl acetate were added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate twice. The organic layer was washed with brine and dried over sodium sulfate. The solids were removed by filtration and the solvents of the filtrate were removed under reduced pressure. The crude was purified via silica column chromatography using a heptane to ethyl acetate gradient to afford a pale yellow oil, G-1. ¹ H NMR (400 MHz, CHLOROFORM-cf) δ ppm 1 .30 (t, J=7.2 Hz, 3 H), 2.28 (s, 3 H), 4.27 (q, J=7.2 Hz, 2 H), 4.41 (s, 1 H), 4.58 (d, J=1 1 .8 Hz, 1 H), 4.75 (d, J=1 1 .8 Hz, 1 H), 7.32 - 7.43 (m, 5 H)

Preparation of intermediate H-1.

Into a 20 ml_ microwave vial was placed intermediate G-1 (500 mg, 2.12 mmol), ethanol (5ml_), and guanidine carbonate (200 mg, 2.22 mmol). The vial was sealed and allowed to react at 120°C with stirring for 4 hours. The solvents were removed under reduced pressure. Water (25 ml_) was added. The mixture was brought to pH=5 via careful addition of acetic acid. The precipitate was isolated via filtration to afford a white solid, H-1.

¹ H NMR (400 MHz, CHLOROFORM-cf) δ ppm 1 .88 (s, 3 H), 4.85 (s, 2 H), 6.38 (br. s., 2 H), 7.24 - 7.49 (m, 5 H), 1 1 .16 (s, 1 H) Preparation of intermediate G-2.

F-1 G-2

Step 1 . Sodium phenolate was prepared by evaporating equimolar portions of phenol and sodium hydroxide in a 1 L round bottom flask on the rotary evaporator. Toluene is used in the azeotropic removal of water.

Step 2. Sodium phenolate (1 16 g, 1 mol) prepared in step 1 and toluene (1 L) were placed in a 2L three-necked flask fitted with mechanical stirrer, addition funnel, and reflux condenser with drying tube. The suspension was heated to reflux, then ethyl a-chloroacetoacetate (165 g, 1 mol) was added with stirring through the addition funnel where the reaction continues heating at reflux for 4 hours. The light brown suspension is cooled to room temperature, extracted with water (2 x 500 mL), and dried (anhydrous magnesium sulfate). The solids were removed via filtration and the solvents of the filtrate were removed under reduced pressure. The crude is used in the next step without purification. Preparation of intermediate H-2.

Into a 100 mL round bottom flask equipped with a magnetic stir bar and reflux condenser was added intermediate G-2 (1 g, 4.5 mmol), ethanol (50 mL), and guanidine carbonate [593-85-1 ](203 mg, 2.25 mmol). The reaction mixture is brought to reflux for 15 hours. The solvent was removed under reduced pressure. Water (25 mL) was added. The mixture was brought to pH=5 via careful addition of acetic acid. The precipitate was isolated via filtration to afford a white solid, H-2. This is used without further purification in the next step. Preparation of intermediate J-1.

H-2 J-1

Into a 50 mL round bottom flask equipped with a magnetic stir bar and reflux condenser was added intermediate H-2 (500 mg, 2.3 mmol) and POCI3 (20 mL). The suspension was heated to reflux with stirring for 6 hours. The solvents were removed under reduced pressure to afford a crude brown oil, J-1. No further purification was done. The compound was used as such in the subsequent step. Preparation of 3.

dioxane

120°C, 15h

J-1

Into a 50 mL sealed tube equipped with a magnetic stir bar was placed intermediate J-1 (1 50 mg, 0.64 mmol), n-butylamine (70 mg, 0.96 mmol), basic alumina (100 mg), and dioxane (10 mL). The tube was sealed, placed in an oil bath at 120°C, and the reaction was heated with stirring for 15 hours. The vessel was cooled to room temperature and the cap was carefully removed. The contents were poured into a round bottom flask where the solvents were removed under reduced pressure. The crude was purified via silica gel column chromatography using a dichloromethane to 5% methanol in dichloromethane gradient. The best fractions were pooled, and the solvents were removed under reduced pressure to afford 3.

LC-MS: Anal. Calcd. For Ci ₅ H ₂ oN ₄ 0: 272.16; found 273 [M+H] ^{+ 1} H NMR (300 MHz, CHLOROFORM-cf) δ ppm 0.80 (t, J=7.3 Hz, 3 H), 1 .20 (dq, J=15.0, 7.3 Hz, 2 H), 1 .33 - 1 .47 (m, 2 H), 1 .98 (s, 3 H), 3.20 - 3.34 (m, 2 H), 4.74 (br. s. , 2 H), 4.79 (br. s. , 1 H), 6.78 - 6.84 (m, 2 H), 6.91 - 7.01 (m, 1 H), 7.18 - 7.28 (m, 2 H)

Preparation of 4

n-butylamine

ethanol

120°C CuO

microwave ammonium bicarbonate

Step 1 .

Into a 20 mL microwave vial was added commercially available 2,4-dichloro-5- methoxy pyrimidine (300 mg, 1 .68 mmol), ethanol (5 mL), and n-butylamine (0.166 mL, 1 .68 mmol). The vial is sealed then heated in the microwave for 10 minutes at 120°C. LC-MS shows complete conversion. The solvents were removed under reduced pressure. The crude is used as such in step 2.

Step 2.

Compound from step 1 was placed into a 20 ml_ pressure vessel with aqueous ammonia (10 ml_) and to this was added ammonium bicarbonate (200 mg, 2.6 mmol), and CuO (24 mg, 0.17 mmol, 0.1 eq). The vessel was sealed and the mixture was heated to 120°C with stirring for 24 hours. The reaction mixture was extracted 3 times with 5ml_ dichloromethane:methanol 9: 1 and the volatiles were removed under reduced pressure. The compound was filtered through silica eluting with dichloromethane:methanol 9: 1 and the volatiles were removed under reduced pressure. The residue was purified by reversed phase chromatography.

LC/MS: Anal. Calcd. For C ₉ Hi ₆ N ₄ 0: 196.13; found 197[M+H] ⁺

1 H NMR (400 MHz, CHLOROFORM-cf) δ ppm 0.97 (t, J=7.3 Hz, 3 H), 1 .35 - 1 .48 (m, 2 H), 1 .56 - 1 .68 (m, 2 H), 3.44 - 3.52 (m, 2 H), 3.80 (s, 3 H), 5.86 (s, 1 H), 5.97 (s, 2 H), 7.07 - 7.14 (m, 1 H)

Preparation of 5.

Step 1 .

Into a 16 x 100 test tube was placed intermediate D-2 (180 mg, 0.66 mmol), DMF (5 ml_), propyl iodide (1 1 1 mg, 0.656 mmol), and cesium carbonate (320 mg, 0.98 mmol). The reaction was allowed to stir at room temperature for 15 hours. The solids were removed by filtration, and the solvents of the filtrate were removed under reduced pressure. The crude was purified via silica gel chromatography using a dichloromethane to 10% methanol in dichloromethane gradient. The best fractions were pooled, the solvents were removed under reduced pressure to afford a white solid.

Step 2.

Into a 10 ml_ microwave vial was placed the above white solid (100 mg), ammonium hydroxide (1 ml_) and ethanol (1 ml_). The vial was sealed and heated with stirring to 175°C for 10 minutes. LC-MS shows complete conversion to product. The solvents were removed under reduced pressure. The crude was purified via silica gel chromatography using a dichloromethane to 10% methanol in dichloromethane gradient. The best fractions were pooled, the solvents were removed under reduced pressure to afford a colorless oil. Addition of one equivalent of HCI (using 5 to 6N HCI in isopropanol) affords a white solid, 5.

LC/MS: Anal. Calcd. For CnH ₂ oN ₄ 0: 224.16; found 225[M+H] ⁺

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.90 (t, J=7.3 Hz, 3 H), 0.98 (t, J=7.4 Hz, 3 H), 1 .20 - 1 .35 (m, 2 H), 1 .54 (t, J=7.2 Hz, 2 H), 1 .69 - 1 .75 (m, 2 H), 3.40 (d, J=7.0 Hz, 2 H), 3.87 (t, J=6.5 Hz, 2 H), 7.39 (d, J=5.5 Hz, 1 H), 7.46 (br. s., 2 H), 8.28 - 8.37 (m, 1 H)

Synthetic Scheme for the preparation of AA-9

AA-7 AA-8 AA-9 Synthesis of intermediate AA-3

AA-1 AA-3

To a solution of valeraldehyde (43 g, 500 mmol) in THF (1 L) was added AA-2 (200 g, 532 mmol) and the reaction mixture was stirred for 16 hours at room temperature. The solvents were evaporated and the residue was diluted in petroleum ether and filtered. The solvents of the filtrate were removed under reduced pressure and the residue was purified by silica chromatography using a petroleum ether to 3% ethyl acetate in petroleum ether gradient to give AA-3 (90 g) as a colorless oil. ¹ H NMR (400 MHz, CDCI ₃ ): δ ppm 6.81 -6.77 (m, 1 H), 5.68-5.64 (td, J=1 .2Hz, 15.6 Hz, 1 H), 2.1 1 -2.09 (m, 2H), 1 .406 (s, 9H), 1 .38-1 .26(m, 4H), 0.85-0.81 (t, J=7.2Hz, 3H).

Synthesis of compound AA-5

AA-3 AA-5 n-butyl lithium (290ml_, 725mmol, 1 .5eq.) was added to a stirred solution of AA-4 (165 g, 781 mmol) in THF (800 mL) at -78°C. The reaction mixture was stirred for 30 minutes then AA-3 (90 g, 488.4 mmol) in THF (400 mL) was added and the reaction was stirred for 2 hours at -78°C. The mixture was quenched with sat., aq. NH ₄ CI solution and warmed to room temperature. The product was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried and evaporated. The residue was purified by column chromatography eluting with 5% ethyl acetate in petroleum ether to afford a colorless oil, AA-5 (132 g). ¹ H NMR (400 MHz, CDCI ₃ ): δ ppm 7.36-7.16 (m, 10H), 3.75-3.70 (m, 2H), 3.43- 3.39 (d, J=15.2Hz, 1 H), 3.33-3.15 (m, 1 H), 1 .86-1 .80 (m, 2H), 1 .47-1 .37 (m, 2H), 1.32 (s, 9H), 1 .26-1 .17 (m, 7H), 0.83-0.79 (t, J=7.2Hz, 3H).

Synthesis of AA-6

AA-5 (130 g, 328 mmol) was dissolved in THF (1 .5 L) and LAH (20 g, 526 mmol) was added at 0°C in small portions. The resulting mixture was stirred at the same temperature for 2 hours and then allowed to warm to room temperature. The mixture was quenched with a sat. aq. NH ₄ CI solution. The product was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried and evaporated. The combined organic layers were dried over sodium sulfate, the solids were removed via filtration and concentrated to afford crude AA-6 (100 g), which was used in the next step without further purification. ¹ H NMR (400 MHz, CDCI ₃ ): δ ppm 7.33-7.14 (m, 10H), 3.91 -3.86 (m, 1 H), 3.80- 3.77 (d, J=13.6Hz, 1 H), 3.63-3.60 (d, J=13.6Hz, 1 H), 3.43-3.42 (m, 1 H), 3.15- 3.10 (m, 1 H), 2.70-2.63 (m, 2H), 1 .65-1 .28 (m, 10H), 0.89-0.81 (m, 3H).

Synthesis of AA-9

HCI/EtOAc

EtOAc

AA-9

A solution of AA-6 (38 g, 1 16.75 mmol) and 10% Pd/C in methanol (200 mL) was hydrogenated under 50 PS I hydrogen at 50°C for 24 hours. The reaction mixture was filtered and the solvent was evaporated to give crude product AA-7 (17 g).

The crude product was dissolved in dichloromethane (200 mL), triethylamine (26.17 g, 259.1 mmol) and di-fe/f-butyl dicarbonate (84.7 g, 194.4 mmol) was added at 0°C. The resulting mixture was stirred at room temperature for 16 hours. The mixture was partitioned between dichloromethane and water. The organic phase was washed with brine, dried and evaporated. The residue was purified by silica gel chromatography eluting with 20% ethyl acetate in petroleum ether to give AA-8 (13 g) as colorless oil. 1H NMR (400 MHz, CDCI ₃ ): δ ppm 4.08-4.03 (br, 1 H), 3.68 (m, 1 H), 3.58-3.55 (m, 2H), 3.20-2.90(br, 1 H), 1 .80-1 .73 (m, 1 H), 1 .42-1 .17 (m, 15 H), 0.85-0.82(t, J=6.8Hz, 3H).

AA-8 (42 g, 0.182 mol) was dissolved in dioxane (200 mL) and dioxane/HCI (4M, 200 mL) was added at 0°C. The resulting mixture was stirred at room temperature for 2h. The solvent was evaporated to afford the crude product. A dichloromethane/petroleum ether mixture (50 mL, 1 : 1 , v/v) was added to the crude product, and the supernatant was decanted. This procedure was repeated two times to obtain an oil, AA-9 (26.6 g). ¹ H NMR (400 MHz, DMSO-d ₆ ): δ ppm 8.04 (s, 3H), 3.60-3.49 (m, 2H), 3.16- 3.15 (m, 1 H), 1 .71 -1 .67 (m, 2H), 1 .60-1 .55(m, 2H), 1 .33-1 .26 (m, 4H), 0.90- 0.87 (t, J=6.8Hz, 3H).

Preparation of AA-10

HO^ NH ₂ HCI

/

AA-10

AA-10 was prepared according to the preparation of AA-9, using butyraldehyde instead of valeraldehyde.

¹ H NMR (400 MHz, DMSO-d ₆ ):6 ppm 8.07 (s, 3H), 4.85 (br, 1 H), 3.57-3.45 (m, 2H), 3.14-3.12 (m, 1 H), 1 .70-1 .64 (m, 2H), 1 .56-1 .49 (m, 2H), 1 .38-1 .30 (m, 2H), 0.90-0.80 (t, J=6.8Hz, 3H).

Preparation of 74

Step 1 . 3,4-dimethoxycinnamic acid (5 g, 24 mmol) was dissolved in THF (100 ml_). Raney Nickel was added to this solution under a N ₂ atmosphere. The reaction mixture was exposed to a hydrogen atmosphere and stirred 15 hours at room temperature. The reaction mixture was filtered over a cartridge packed with diatomateous earth and the solvent of the filtrate was removed under reduced pressure. The residue was used as such in the next step. LC-MS: Anal. Calcd. For CiiHu0 ₄ : 210.09; found 209[M-H]

Step 2. 3-(3,4-dimethoxyphenyl)propanoic acid was dissolved in THF (100 mL). Borane-dimethyl sulfide complex (2M in diethyl ether, 20 mL, 40 mmol) was added. The reaction mixture was stirred overnight at room temperature. Methanol was added slowly to quench the reaction mixture, then silica was added and the volatiles were removed under reduced pressure. The residue was purified on silica using a heptane to ethyl acetate gradient yielding the product as an oil. This was used as such in the next step.

LC-MS: Anal. Calcd. For CnHi _e 0 ₃ : 196.1 1 ; found 195[M-H]

Step 3. 3-(3,4-dimethoxyphenyl)propan-1 -ol (3.8 g, 19.5 mmol) and triethylamine (3.8 mL, 27.3 mmol) were dissolved in acetonitrile (15 mL) and then methanesulfonyl chloride (1.5 mL, 19.5 mmol) was added. The reaction mixture was shaken overnight at room temperature. The volatiles were removed under reduced pressure and the residue was purified via silica gel chromatography using a heptane to ethyl acetate gradient yielding the product as a clear oil.

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 1 .91 - 2.01 (m, 2 H), 2.58 - 2.64 (m, 2 H), 3.17 (s, 3 H), 3.72 (s, 3 H), 3.75 (s, 3 H), 4.19 (t, J=6.4 Hz, 2 H), 6.71 - 6.76 (m, 1 H 6.81 - 6.89 (m, 2 H)

D-4 D-5

Step 4. A solution of D-4 (400 mg, 1 mmol), cesium carbonate (51 1 mg, 1 .6 mmol) and 3-(3,4-dimethoxyphenyl)propyl methanesulfonate (430 mg, 1 .6 mmol) in acetone (50 mL) was heated to 50°C for 15 hours. The reaction mixture was placed in the centrifuge and the supernatant was decanted then evaporated to dryness. The residue was purified via silica column chromatography using a gradient from heptane to ethyl acetate. The fractions containing the product were pooled and the solvents were removed under reduced pressure to afford D-5.

LC-MS: Anal. Calcd. For C29H44N4O7: 560.32; found 561 [M+H] ⁺

Step 5. The boc-protected compound was dissolved in dichloromethane (5 mL) and 6M HCL in isopropanol (3 mL) was added. The reaction mixture was stirred 15 hours at room temperature. The volatiles were removed under reduced pressure. Ether (5 mL) was added and a precipitate formed, 74 was isolated by filtration then dried in the vacuum oven for 15 hours.

Preparation of 75

B-2 AA-9 75 Step 1 . Intermediate B-2 was prepared according to the method described for the preparation of intermediate B-1.

Step 2. To a solution of B-2 (1 g, 3.62 mmol) and DBU (5.4 mL, 36 mmol) in acetonitrile (20 mL) was added BOP (2.08 g, 4.71 mmol) and the reaction mixture became transparent and was stirred for 15 minutes at room temperature. AA-9 (910 mg, 5.43 mmol) was added and the reaction mixture was stirred for 2 days at 50°C. The volatiles were removed under reduced pressure and the residue was purified on silica using a dichloromethane to 10% methanol in dichloromethane gradient. The best fractions were pooled and the solvents were removed under reduced pressure. The crude was reconstituted in dichloromethane (2 mL) then HCI in diethylether was added to form the HCI salt. The precipitate was isolated by filtration and dried in the vacuum oven to afford compound 75. Preparation of 76

C-1 D-6

Step 1 . C-1 (2 g, 8.49 mmol), L-norvalinol (1.75 g, 17 mmol) and diisopropylethylamine (5.85 mL, 34 mmol) were dissolved in acetonitrile (200 mL) in a 500 mL teflon coated pressure vessel and heated to 130°C for 15 hours. The mixture was allowed to cool to room temperature, the volatiles were removed under reduced pressure and the crude was purified via silica gel column chromatography using a gradient from dichloromethane to 10% methanol in dichloromethane. The best fractions were pooled and the solvents were removed under reduced pressure to afford intermediate D-6.

LC-MS: Anal. Calcd. For C16H22N4O2: 302.17; found 303 [M+H] ⁺

D-6 D-7 Step 2. D-6 (2 g, 6.61 mmol) was heated to reflux in acetic anhydride (100 mL) in a 250 mL round bottom flask for 4 hours. The volatiles were removed under reduced pressure and the residue was purified via silica gel column chromatography using a heptane to ethyl acetate gradient yielding a yellow oil,

LC-MS: Anal. Calcd. For C22H28N4O5: 428.21 ; found 429 [M+H] ⁺

Step 3. D-8 was prepared according to the method to prepare intermediate D-2.

LC-MS: Anal. Calcd. For C15H22N4O5: 338.16; found 339 [M+H] ⁺

Step 4. Intermediate D-9 was prepared according to the method described example 75 from intermediate D-4.

LC-MS: Anal. Calcd. For C15H22N4O5: 338.16; found 339 [M+H] ⁺

D-9 76

Step 5. Deprotection of D-9 was performed according to the method described in step 2 of compound 5 to afford 76.

Preparation of compound 77

D-4 D-10

Step 1 . D-10 was prepared from D-4 according to the method to prepare example 5, purification via silica column with heptane to ethyl acetate gradient. LC-MS: Anal. Calcd. For C27H38N4O7: 530.27; found 531 [M+H] ^{+ 1} H NMR (400 MHz, CHLOROFORM-cf) δ ppm 0.93 (t, J=7.3 Hz, 3 H), 1 .37 (dd, J=14.9, 7.4 Hz, 2 H), 1 .53 - 1 .62 (m, 2 H), 3.40 - 3.50 (m, 2 H), 3.92 - 3.95 (m, 3 H), 5.13 (s, 2 H), 5.33 (s, 1 H), 7.46 - 7.52 (m, 1 H), 7.56 - 7.62 (m, 1 H), 7.73 (s, 1 H), 8.05 (dt, J=7.7, 1.4 Hz, 1 H), 8.09 (d, J=1 .5 Hz, 1 H)

D-10 D-11

Step 2. D-10 (2.14 g, 3.91 mmol) was dissolved in anhydrous THF (250 ml_). Lithium aluminum hydride (1 M in THF, 5.87 ml_, 5.87 mmol) was added dropwise and the reaction mixture was stirred for 3 hours at room temperature. NH ₄ CI (sat., aq.) was added drop wise to the reaction mixture and the precipitated salts were removed by filtration and washed with THF. The filtrate was evaporated to dryness and crude D-11 was used as such in the next step. LC-MS: Anal. Calcd. For C21 H30N4O4: 402.23; found 403 [M+H] ⁺

Step 3. D-1 1 (1 .57 g, 3.91 mmol) was dissolved in dichloromethane (20 ml_) and to it was added HCI (6 M in isopropanol, 50 ml_). The reaction mixture stirred for 16 hours at room temperature. The volatiles were removed under reduced pressure and the crude was purified via silica column using a dichloromethane to 10% dichloromethane in methanol gradient yielding 77 as an oil which solidified on standing.

Preparation of 78

D-4 D-1 2

Step 1 . A solution of D-4 (0.5 g, 1 .31 mmol), 3-pyridazinylmethanol (158 mg, 1 .44 mmol) and triphenylphosphine (377 mg, 1 .44 mmol) in anhydrous THF (4 ml_) was cooled to 0°C and a solution of DIAD (0.28 ml_, 1 .44 mmol) was added dropwise at 0°C. After addition, the reaction mixture was stirred for 3 hours at ambient temperature. The solvent was quenched with water (10 ml_), stirred for 10 minutes and the volatiles were removed under reduced pressure. The water layer was extracted with dichloromethane, the organic layers were combined, and the solvent was removed under reduced pressure. The crude was purified via silica gel column chromatography using a heptane to ethyl acetate gradient. The best fractions were combined, the solvents were removed under reduced pressure to afford D-12.

LC-MS: Anal. Calcd. For C23H34N6O5: 474.26; found 475 [M+H] ⁺

D-12 78

Step 2. D-1 1 (620 mg, 1 .31 mmol) was dissolved in dichloromethane (10 ml_) and to it was added HCI (6 M in isopropanol, 10 ml_). The reaction mixture stirred for 15 hours at room temperature. The volatiles were removed under reduced pressure and the residue was purified by reversed phase chromatography to afford 78.

Preparation of 79

B-1 B-5

Step 1 . In a 500 ml_ flask a mixture of B-1 (30 g, 138 mmol) and sulfuric acid (3 ml_) in acetic anhydride (300 ml_) was heated to 90°C for 3 hours. The reaction cooled to room temperature and the precipitate was isolated by filtration, washed with diisopropyiether and dried in vacuo at 50°C to obtain a white solid, B-5.

Step 2. In a 400 mL multimax reactor a mixture of B-5 (21 .8 g, 84 mmol) in acetonitrile (244 mL) was stirred at 30°C under a gentle stream of nitrogen. Phosphoryl chloride (18.14 mL, 195 mmol) was added dropwise over a period of 5 minutes. After addition, the reaction mixture was heated to 45°C and the mixture was stirred for 15 minutes, then DIPEA (33 mL, 195 mmol) was added slowly over a period of 1 .5 hours. The reaction was stirred at 45°C until completion (monitored by LC-MS). A solution of sodium ethanoate (65 g ) in water (732 mL) was heated in a 2 L flask to 35°C and the reaction mixture was portioned into this solution over a period of 5 minutes. The temperature is kept between 35-40°C via an external cooling bath. The mixture was allowed to reach ambient temperature and stirring was continued for 1 hour. The precipitate was isolated by filtration, washed with water and dried in vacuo at 50°C to obtain C-2 as a solid.

LC-MS: Anal. Calcd. For C13H12CIN3O2: 277.06; found 278 [M+H] ⁺

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 2.1 1 (s, 3 H), 5.31 (s, 2 H), 7.33 - 7.39 (m, 1 H), 7.43 (t, J=7.2 Hz, 2 H), 7.46 - 7.51 (m, 2 H), 8.59 (s, 1 H), 10.65 (s, 1 H)

C-2 D-13

Step 3. A solution of intermediate C-2 (5.9 g, 21.2 mmol), methyl (2S)-2- aminohexanoate (5.79 g, 31 .9 mmol) and triethylamine (14.8 mL, 106 mmol) in acetonitrile (100 mL) was heated to reflux for 4 days. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane and washed with brine. The organic layer was dried (magnesium sulfate) then purified directly via silica column using a gradient of dichloromethane to 10% methanol in dichloromethane. The best fractions were pooled and the solvents were removed under reduced pressure to afford D-13.

LC-MS: Anal. Calcd. For C20H26N4O4: 386.20; found 387 [M+H] ⁺

D-13 D-14

Step 2. D-13 (3.7 g, 9.57 mmol) was dissolved in anhydrous THF (100 ml_). Lithium aluminum hydride (1 M in THF, 9.6 ml_, 9.6 mmol) was added dropwise and the reaction mixture stirred for 3 hours at room temperature. NH ₄ CI (sat., aq.) was added drop wise to the reaction mixture and the precipitated salts were removed via filtration and washed with THF. The filtrate was evaporated to dryness and the residue was purified via silica gel column chromatography using a dichloromethane to 10% methanol in dichloromethane gradient. The best fractions were combined and the solvents were removed under reduced pressure to afford D-14.

LC-MS: Anal. Calcd. For C19H26N4O3: 358.20; found 359 [M+H] ⁺

D-14 D_ ₁₅

Step 3. D-15 was prepared according to the method described for intermediate D-2. Used without purification in the next step.

LC-MS: Anal. Calcd. For C12H20N4O3: 268.15; found 269 [M+H] ⁺

D-15 D-16

Step 4. A mixture of D-15 (210 mg, 0.78 mmol) and cesium carbonate (765 mg, 2.35 mmol) in DMF (25 mL) was heated to 60°C with stirring then a solution of 5-(chloromethyl)-1 ,3-dimethyl-1 H-pyrazole (1 13 mg, 0.78 mmol) in DMF(10 mL) was added drop wise. The reaction mixture was stirred for 1 hour at 60°C. The solids were removed by filtration and the solvent was removed under reduced pressure. Crude D-16 was used as such in the next step.

LC-MS: Anal. Calcd. For CisHasNeOs: 376.22; found 377 [M+H] ⁺

D-16 ' ³

Step 5. Into a 30 mL glass tube was placed D-16 (295 mg, 0.78 mmol) and NaOCH ₃ (30% in methanol, 2 mL) and methanol (20 mL) and the mixture was stirred at 60°C overnight. The reaction mixture was purified via reverse phase liquid chromatography (Sunfire Prep C18 OBD 10mm, 30 x 150 mm. Mobile phase 0.25% NH ₄ OAc solution in water, methanol) to afford 79 as the free base. reparation of 80

D-15 D-17

Step 1 . Intermediate D-17 was prepared according to the method used for D-16 via alkylation of D-15.

LC-MS: Anal. Calcd. For C19H24N6O3: 384.19; found 385 [M+H] ⁺

D-17 80

Step 2. In a 30 mL glass tube D-17 (301 mg, 0.78 mmol) and NaOCH ₃ (30% in methanol, 2 mL) were dissolved in methanol (20 mL) and stirred at 60°C overnight. 10 mL of water was added to the reaction mixture and it was stirred for 2 hours at 60°C. The reaction mixture was purified via reverse phase liquid chromatography (Sunfire Prep C18 OBD 10mm, 30 x 150 mm. Mobile phase 0.25% NH ₄ OAc solution in water, methanol) yielding 80 as a powder.

A solution of intermediate C-2 (2 g, 7.2 mmol), AA-9 (3.02 g, 18 mmol) and triethylamine (5 mL, 36 mmol) in acetonitrile (75 mL) was heated to reflux for 6 hours. The reaction mixture was cooled down and the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane and washed with brine. The organic layer was loaded on a silica cartridge and a gradient of dichloromethane to 10% methanol in dichloromethane was applied. The fractions containing the product were evaporated to dryness yielding a white powder, D-18.

LC-MS: Anal. Calcd. For C20H28N4O3: 372.22; found 373 [M+H] ^{+ 1} H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.77 - 0.92 (m, 3 H) 1 .15 - 1 .36 (m, 4 H) 1 .42 - 1 .72 (m, 4 H) 2.12 (s, 3 H) 3.35 - 3.42 (m, 2 H) 4.1 1 - 4.24 (m, 1 H) 4.35 - 4.52 (m, 1 H) 6.42 (d, J=8.80 Hz, 1 H) 7.42 (s, 1 H) 9.63 (br. s., 1 H)

D-19 was prepared from D-18 according to the method employed for intermediate D-2.

LC-MS: Anal. Calcd. For C13H22N4O3: 282.1 ; found 283 [M+H] ⁺

D-19 D-20

D-20 was prepared from D-19 according to the method to prepare D-17. LC-MS: Anal. Calcd. For C19H30N6O3: 390.24; found 391 [M+H] ⁺

81 was prepared from D-20 according to the method to prepare compound 79. Preparation of 82

B-3

Step 1 . Intermediate B-3 was prepared according to the method described for B-1 .

LC-MS: Anal. Calcd. For C13H15N3O2: 245.12; found 246 [M+H] ^{+ 1} H NMR (400 MHz, DMSO-d ₆ ) δ ppm 1 .79 - 1 .93 (m, 2 H), 2.66 (t, J=7.8 Hz, 2 H), 3.76 (t, J=6.4 Hz, 2 H), 6.54 (br. s., 2 H), 7.1 1 - 7.21 (m, 3 H), 7.22 - 7.29 (m, 3 H), 1 1 .46 (br. s, 1 H)

B-3 C-3

Step 2. In a 250 mL round bottom flask a mixture of B-3 (15 g, 61 .15 mmol) in POCI3 (150 mL) was heated to reflux and stirred for 2 hours. The reaction was allowed to cool and the solvent was removed under reduced pressure. The residual fraction was triturated with diisopropylether. The formed precipitate isolated by filtration, washed with diisopropylether and dried under vacuo at 50°C to obtain a solid, C-3, used as such in the next step.

LC-MS: Anal. Calcd. For C13H14CIN3O: 263.08; found 264 [M+H] ⁺

82

Step 3. Into a 20 mL tube was placed C-3 (0.45 g, 1 .05 mmol), L-2-aminohexanoic acid-methyl ester HCI (0.48 g, 2.62 mmol), DIPEA (1 .18 mL, 6.82 mmol), and acetonitrile (5 mL). The tube was sealed and heated in the microwave for 1 .5 hours at 120°C. The reaction was allowed to cool and the solvent was removed under reduced pressure.

The crude mixture was purified by Prep HPLC on (RP Vydac Denali C18 - 10 μηπ, 250 g, 5 cm). Mobile phase (0.25% NH ₄ OAc solution in water, methanol), the desired fractions were collected and evaporated to dryness. The residual fraction was dissolved in a mixture of dichloromethane/methanol and poured over a acid modified solid phase extraction cartridge (SCX). The product was released using with NH ₃ 7N in methanol. The collected solution was concentrated under reduced pressure to obtain the desired solid, 82. Preparation of 83

B-4

Step 1 . Intermediate B-4 was prepared according to the method to prepare B-1.

LC-MS: Anal. Calcd. For C14H17N3O3: 275.13; found 276 [M+H] ^{+ 1} H NMR (400 MHz, DMSO-d ₆ ) δ ppm 3.63 (dd, J=5.4, 3.9 Hz, 2 H), 3.95 (dd, J=5.4, 3.6 Hz, 2 H), 4.50 (s, 2 H), 6.33 (br. s., 2 H), 7.22 - 7.29 (m, 2 H), 7.30 - 7.36 (m, 4 H), 10.71 - 1 1.58 (m, 1 H)

B-4 C-4 Step 2. Into a 250 mL round bottom flask was placed B-4 (10 g, 38.27 mmol) and POCI3 (75 mL). The mixture was heated to reflux and stirred for 5 hours. The reaction mixture was allowed to reach room temperature and stirred for 15 hours. The solvent was removed under reduced pressure. Crude C-4 was used as such in the next step. LC-MS: Anal. Calcd. For C12H12CIN3O2: 265.06; found 266 [M+H] ⁺

C-4 83

Step 3. Into a 50 mL tubes was placed C-4 (10 g, 35.75 mmol), n-butylamine (10.6 mL, 107.25 mmol) and DIPEA (30.8 mL, 178.75 mmol) in acetonitrile (40 mL). The mixture was heated to 120°C under microwave irradiation for 3 hours. The combined reaction mixtures were concentrated under reduced pressure and the residual oil was dissolved in dichloromethane and washed with 1 N HCI and water. The organic layer was dried (magnesium sulfate), the solids were removed by filtration and the solvent of the filtrate were removed under reduced pressure to obtain an red-brown foam, 83.

Preparation of 84

Step 1 . Into a 500 ml_ round bottom flask was placed 83 (13.5 g, 25.6 mmol), Boc-anhydride (27.94 g, 128 mmol) and acetonitrile (150 ml_). The yellow solution was stirred at reflux for 16 hours. The solvent was removed under reduced pressure. The residual fraction was dissolved in dichloromethane and washed with a saturated aqueous NaHC03 solution and water. The organic layer was dried (magnesium sulfate), the solids were removed via filtration, and the solvents of the filtrate were removed under reduced pressure to obtain an oil, D-20

LC-MS: Anal. Calcd. For C22H32N4O4: 416.24; found 417 [M+H] ⁺

Step 2. Into a 1 L erlenmeyer was suspended 10% Pd/C (4 g) in methanol (350 ml_) under N ₂ gas flow, then D-20 (14.3 g, 34.33 mmol) was added. The mixture was stirred at 50°C under a hydrogen atmosphere until 1 equivalent of hydrogen was absorbed. The catalyst was removed by filtration over packed decalite. The solvent of the filtrate was removed under reduced pressure to obtain an oil, D-21. The residue was used as such in the next step.

LC-MS: Anal. Calcd. For C15H26N4O4: 326.20; found 327 [M+H] ⁺

D-21 D-22

Step 3. Into a 1 L round bottom flask a solution of D-21 (8.7 g, 26.66 mmol) and triethylamine (7.41 mL, 53.31 mmol) in acetonitrile (300 mL) was stirred at ambient temperature and methanesulfonyl chloride (3.1 mL, 40 mmol) was added. After addition, the reaction mixture was stirred for 1 .5 hours at room temperature. The solvent was removed under reduced pressure. The crude was dissolved in ethyl acetate and washed with saturated aqueous NaHC03. The organic layers were combined, dried (magnesium sulfate), the solids were removed by filtration and the solvent of the filtrate were evaporated to dryness to obtain D-22 as an oil.

LC-MS: Anal. Calcd. For 404.17; found 405 M+H] ⁺

D-22 D-23 Step 4. Into a 30 mL glass tube was placed a mixture of 4-hydroxypiridine (94 mg, 0.99 mmol) and Cs ₂ C0 ₃ (0.8 g, 2.47 mmol) in acetonitrile (10 mL). The vial was sealed and shaken at ambient temperature for 1 hour. D-22 (400 mg, 0.99 mmol) as a solution in acetonitrile (10 mL) was added to the reaction mixture and shaken for an additional 18 hours at room temperature. Cesium carbonate (320 mg, 1 mmol) was added and the mixture was shaken for 1 day at room temperature. The solvent was removed under reduced pressure and the crude was treated with a mixture of dichloromethane/methanol, 95/5 and shaken for 1 h, then filtered over 2 g of packed silica. The filtrate was concentrated under reduced pressure and D-23 was used as such in the next step.

LC-MS: Anal. Calcd. For C20H29N5O4: 403.22; found 404 [M+H] ⁺

D-23 84

Step 5. D-23 was deprotected to afford 84 using the method applied to deprotect 78.

Preparation of 85

D-4 D-24

Step 1 . Into a 250 ml_ round bottem flask equipped with a magnetic stir bar was placed D-4 (0.35 g, 5.23 mmol) and cesium carbonate (0.89 g, 2.75 mmol) in acetonitrile (20 ml_). The mixture was stirred at ambient temperature for 30 minutes. A solution of the alkyl halide (0.19 g, 1 mmol) in acetonitrile (5ml_) was added and the reaction mixture was stirred for 1 day at room temperature. The reaction was completed and the salts were removed by filtration. The filtrate was concentrated under reduced pressure and the crude was purified by silica column chromatography using a heptane to ethyl acetate gradient to afford intermediate D-24. LC-MS: Anal. Calcd. For C24H37N7O7: 535.28; found 536 [M+H] ⁺

Step 2. Into a 100 ml_ erlenmeyer flask was suspended Pt/C, 5% (100 mg) in thiophene (0.25 ml_ ) and methanol (20 ml_) under a blanket of nitrogen gas, then D-24 (130 mg, 0.24 mmol) was added. The reaction mixture was stirred at 50°C under a hydrogen atmosphere. The catalyst was removed by filtration over packed decalite. The solvents of the filtrate were removed under reduce pressure to obtain D-25 as an oil, that was used as such in the next step.

LC-MS: Anal. Calcd. For C24H39N7O5: 505.30; found 506 [M+H] ⁺

Step 3. Intermediate D-25 is deprotected to afford 85 according to the method used to prepare 78.

Preparation of 86

A-2

Step 1 . Into a 100 mL round bottom flask was placed sodium azide (6.85 g, 103.76 mmol) in water (12.5 mL) then chloromethyl pivalate (10.6 g, 70.38 mmol) and stirred vigorously at 90°C for 16 hours. The reaction mixture was allowed to cool to room temperature and dichloromethane (20 mL) was added. The organic layer was separated, dried over anhydrous sodium sulfate, the solids were removed by filtration and the solvent of the filtrate was removed under reduced pressure to obtain A-2 as an oil.

LC-MS: Anal. Calcd. For 0 ₆ ΗιιΝ ₃ 0 ₂ : 157.09; found 158 [M+H] ⁺

Step 2. Into a 25 mL tube was placed of D-26 (100 mg, 0.238 mmol), A-2 (37.9 mg, 0.238 mmol), f-butanol (2.5 mL) and water (2.5 mL). The tube was sealed and the mixture was stirred at ambient temperature. Copper(ll) sulfate pentahydrate (3 mg, 0.012 mmol) and L-ascorbic acid sodium salt (15.5 mg, 0.079 mmol) were added. The reaction mixture was stirred for 18 hours at room temperature, then water (2.5 mL) was added. The precipitate was isolated by filtration, washed with water and dried in vacuo at 60°C to obtain a white powder, D-27.

LC-MS: Anal. Calcd. For C27H43N7O7: 577.32; found 578 [M+H] ⁺

Step 3. In a 100 mL round bottom flask a mixture of D-27 (0.1 g, 0.17 mmol) in HCI (5 mL 6M in isopropanol) and dichloromethane (5 mL) was stirred at ambient temperature for 16 hours. The reaction was heated to 65°C and stirred for an additional 16 hours. The solvent was removed under reduced pressure.

The crude product was purified by reverse phase liquid chromatography (RP Vydac Denali C18 - Ι Ομητι, 250 g, 5 cm). Mobile phase (0.25% NH4HCO3 solution in water, methanol), the desired fractions were collected, evaporated, dissolved in methanol and treated with 2M HCI in ether. The solid was isolated by filtration to afford 86 as the HCI salt.

Preparation of 87

C-2 D-28 Step 1 . Into a 100 ml_ round bottom flask was placed a solution of C-2 (500 mg, 1 .8 mmol), AA-10 (692 mg, 4.5 mmol) and triethylamine (0.75 ml_, 5.4 mmol) in acetonitrile (30 ml_). The mixture was heated to 80°C for 16 hours with stirring. The reaction was allowed to cool and the solvent was removed under reduced pressure. The crude was dissolved in dichloromethane and washed with brine. The organic layer was dried (magnesium sulfate), the solids were removed by filtration and the solvent of the filtrate was removed to obtain an oil, D-28.

LC-MS: Anal. Calcd. For Ci ₉ H ₂ 6N 0 ₃ : 358.20; found 359 [M+H] ^{+ 1} H NMR (360 MHz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.32 Hz, 3 H) 1 .19 - 1 .37 (m, 2 H) 1 .38 - 1 .53 (m, 1 H) 1 .53 - 1 .75 (m, 3 H) 2.13 (s, 3 H) 3.38 - 3.48 (m, 2 H) 4.19 - 4.31 (m, 1 H) 5.16 (s, 2 H) 6.69 (d, J=9.15 Hz, 1 H) 7.29 - 7.41 (m, 3 H) 7.45 - 7.53 (m, 2 H) 7.66 (s, 1 H) 9.77 (s, 1 H)

D-28 D-29

Step2. D-29 was prepared according to the method used to prepare D-21 . THF was added to increase the solubility of D-29.

LC-MS: Anal. Calcd. For C12H20N4O3: 268.15; found 269 [M+H] ⁺

D-29 D-30

Step 3. In a 250 mL round bottom flask a mixture of D-29 (5 g, 18.6 mmol) and cesium carbonate (18.2 g, 55.9 mmol) in DMF (80 mL) was stirred at ambient temperature for 30 minutes. The mixture was heated to 60°C and a solution of 2-chloromethyl-3,4-dimethoxy pyridine hydrochloride (3.97 g, 17.7 mmol) in DMF (60 mL) was added dropwise. The reaction mixture was stirred for 2 hours at 60°C. The reaction was allowed to cool and the salts were removed by filtration. The reaction mixture was concentrated under reduced pressure and D-30 was used as such in the next step. LC-MS: Anal. Calcd. For C20H29N5O5: 419.22; found 420 [M+H] ⁺

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.83 (t, J=7.4 Hz, 3 H), 1 .18 - 1 .32 (m, 2 H), 1 .41 - 1 .71 (m, 4 H), 2.14 (s, 3 H), 3.34 - 3.40 (m, 2 H), 3.78 (s, 3 H), 3.91 (s, 3 H), 4.17 - 4.29 (m, 1 H), 4.41 (t, J=5.3 Hz, 1 H), 5.09 (s, 2 H), 6.79 (d, J=8.8 Hz, 1 H), 7.15 (d, J=5.7 Hz, 1 H), 7.75 (s, 1 H), 8.24 (d, J=5.5 Hz, 1 H), 9.75 (s, 1 H)

Step 4. 87 was prepared according to the same method used to prepare 79 from intermediate D-16. 87 was purified by reverse phase chromatography (Hyperprep C18 HS BDS. Mobile phase (Gradient from 90% ammonium bicarbonate in water 0.25%, 10% acetonitrile to 0% ammonium bicarbonate in water 0.25%, 100% acetonitrile). The best fractions were pooled, the solvents were removed under reduced pressure, reconstituted in methanol and treated with 2M HCI in ether and then concentrated under reduced pressure to obtain a white solid, the HCI salt of 87.

88

Isolation of the HCI salt of 87 via reverse phase liquid chromatography led to the concomitant isolation of 88 in low yield. The best fractions were pooled, and the solvents were removed under reduced pressure to afford a white solid, 88. Preparation of 89

A A -8 AA-12

Step 1 . Into a 100 mL round bottom flask was placed AA-8 (2 g, 8.65 mmol), dichloromethane (6 mL), ethyl isocyanate (1.6 mL, 10.38 mmol), and DMAP (21 mg, 0.173 mmol). The reaction mixture was allowed to stir for 16 hours at room temperature. The solvent was removed under reduced pressure and AA-12 was used in the subsequent step without further purification.

LC-MS: Anal. Calcd. For C15H30N2O4: 302.22; found 303 [M+H] ⁺

AA-13

AA-12 Step 2. Into a 100 mL round bottom flask was placed crude AA-12 (2.61 g, 8.65 mmol), and dichloromethane (30 mL). To this solution was added HCI (20 mL, 4M in dioxane). The reation was allowed to stir 3 hours at room temperature.

LC-MS: Anal. Calcd. For C10H22N2O2: 202.17; found 203 [M+H] ⁺

AA-13 4763-35-3 89 Step 3. Into a 100 mL round bottom flask equipped with a magnetic stir bar was placed 2-Amino-4-hydroxy-5-methoxy-pyrimidine (500 mg, 3.54 mmol), anhydrous DMF (30 mL), AA-13 (1 .27 g, 5.31 mmol), DBU (2.12 mL, 14.17 mmol), and BOP (1 .96 g, 4.43 mmol). The reaction mixture was allowed to stir at room temperature for 30 minutes then at 50°C for 16 hours. The solvent was removed under reduced pressure and the residue was partitioned between brine and ethyl acetate. The organic layers were combined, dried (magnesium sulfate), the solids were removed via filtration, and the solvents of the filtrate were removed under reduced pressure. The crude was purified via reverse phase liquid chromatography (RP Vydac Denali C18 - 10 m, 250 g, 5 cm. Mobile phase 0.25% NH4HCO3 solution in water, methanol), the best fractions were pooled, the solvents were removed under reduced pressure to afford 89. Preparation of 264

Step 1 . AA-14 was prepared according to the procedure to prepare AA-10, employing the appropriate starting aldehyde.

LC-MS: Anal. Calcd. For C7H17NO: 131 .13; found 132 [M+H] ⁺

¹ H NMR (400 MHz, CHLOROFORM-cf) δ ppm 0.81 - 0.89 (m, 6 H), 1 .15 - 1 .25 (m, 2 H), 1.33 - 1 .47 (m, 1 H), 1.54 - 1 .69 (m, 2 H), 2.71 (br. s., 3 H), 2.88 - 2.98 (m, 1 H), 3.69 - 3.80 (m, 2 H)

c-5

4763-35-3

Step 2. C-5 was prepared according to the method used to prepare C-2 from the available starting material. The crude was used without further purification. LC-MS: Anal. Calcd. For C ₅ H ₆ CIN ₃ O: 159.02; found 160 [M+H] ⁺

C-5 264

Step 3. C-5 was combined with AA-14 according to the method used to prepare compound 1 , except that acetonitrile was used as a solvent, to afford 264.

Preparation of 278

Step 1 . AA-15 was prepared according to the procedure to prepare AA-10, employing the appropriate starting aldehyde.

LC-MS: Anal. Calcd. For C7H17NO: 131 .13; found 132 [M+H] ⁺

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.81 - 0.89 (m, 6 H), 1 .05 - 1 .20 (m, 1 H), 1 .27 - 1 .40 (m, 1 H), 1 .43 - 1 .77 (m, 3 H), 3.05 - 3.19 (m, 1 H), 3.44 - 3.57 (m, 2 H), 4.82 (br. s., 1 H), 7.94 (d, J=18.6 Hz, 2 H)

278 Step 2. C-5 was combined with AA-15 according to the method used to prepare compound 1 , except that acetonitrile was used as a solvent, to afford 278. Preparation of 295

valeralde yde AA-1 6 11 0-62-3

a) MgS04 (5 equ iv), PPTS (0.05 equ iv), CH ₂ CI ₂ , rt b) HCI in ethe r, filter off byproduct

Step 1 . AA-16 was prepared according to the procedures outlined in

Rev., 2010, Vol. 1 10, No. 6, 3600-3740.

LC-MS: Anal. Calcd. For C ₈ Hi ₇ N: 127.14; found 128 [M+H] ⁺

C-5 278 Step 2. C-5 was combined with AA-16 according to the method used to prepare compound 1 , except that acetonitrile was used as a solvent, to afford 295.

Preparation of 304

1 . LiBHEt ₃ , THF,

2. MgBr ₂ , -78°C

591 -78-6 2. HCI, methanol

3. CH ₃ CHO, -78°C

AA-17 Step 1 . AA-17 was prepared according to the procedures outlined in Chem.

Rev. , 2010, Vol. 1 10, No. 6, 3600-3740.

LC-MS: Anal. Calcd. For C ₈ Hi ₉ NO: 145.15; found 146 [M+H] ⁺

304 Step 2. C-5 was combined with AA-17 according to the method used to prepare compound 1 , except that acetonitrile was used as a solvent, to afford 304.

Table I: Com ounds of formula (I).

Hz, 3

1 (m,

2

Hz, 1 6.7,

1

H)

4

(dt, Hz,

H), 1 (t, 2 2 H), (t,

- 6 2 δ

H), (s, δ 2 H), (t, 1 (s, δ

5.63 (s, - Hz, 2

2 H), δ 2 H), 7.59

δ

4.90 (t, (d δ

2 H), LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

¹ H NM (400 MHz, DMSO-d ₆ ) δ ppm 0.89 (t, J=7.0 Hz, 3 H), 1.29 (dd, J=15.3, 7.5 Hz, 2 H), 1.24 (m, J=3.0 Hz, 2 H), 1.32-

224.16 225 3.23, C 1.38 (m, 3 H), 1.51-1.62 (m, 2

H), 3.40-3.44 (m, 2 H), 3.98

( (q, J=6.9 Hz, 2 H), 7.42 (s, 1 H),

7.49 (br. s., 2 H), 8.39 (t, J=5.8 Hz, 1 H)

^X H NMR (400 MHz,

CHLOROFORM-d) δ ppm 0.94 (t, J=7.3 Hz, 3 H), 1.26 (s, 1 H), 1.37 (dd, J=15.1, 7.5 Hz, 2 H),

288.16 289 0.91, D 1.52-1.63 (m, 2 H), 3.39-3.50

(m, 2 H), 3.88 (s, 3 H), 5.31- 5.44 (m, 1 H), 5.60-5.71 (m, 1 H), 6.87 - 7.01 (m, 3 H), 7.08- 7.15 (m, 1 H), 7.33 (s, 1 H).

^X H NMR (400 MHz,

CHLOROFORM-d) δ ppm 0.86 -

N

0.99 (m, 3 H), 1.18 (d, J=6.5 Hz, 3 H), 1.28- 1.39 (m, 2 H), 1.44-

210.15 211 0.73, D

1.55 (m, 2 H), 3.76 (s, 3 H), 4.08-4.22 (m, 1 H), 4.40 (br. s., 2 H), 4.94 (d, J=7.8 Hz, 1 H), 7.34 (s, 1 H)

^X H NMR (400 MHz,

CHLOROFORM-d) δ ppm 1.82 - 1.93 (m, 2 H), 2.07-2.25 (m, 2

N 250.10 251 0.66, D H), 3.50 (q, J=6.6 Hz, 2 H), 3.77

(s, 3H), 4.54 (br. s., 2 H), 5.21- 5.31 (m, 1 H), 7.39 (s, 1 H)

^X H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.89 (t, J=7.3 Hz, 3 H), 1.24-1.35 (m, 2 H), 1.50 (t, J=7.2 Hz, 2 H), 3.25-3.33 (m, 2

346.16 347 0.56, D H), 3.83 (s, 3 H), 4.88 (s, 2 H),

5.57 (s, 1 H), 6.32 (s, 1 H), 7.33 (d, J=7.8Hz, 1H), 7.36 (s, 1 H), 7.48 (dd, J=7.7, 1.1 Hz, 1 H),

7.54 (d, J=1.0 Hz, 1 H) LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

7.24- 7.29 (m, 1 H), 7.29-7.34 (m, 2 H), 7.35- 7.40 (m, 2 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm0.90 (t,J=7.3 Hz, 3 H), 1.30 (dq,J=14.9, 7.3 Hz, 2 H), 1.51 (quin,J=7.3 Hz, 2 H), 3.26 - 3.32

274.15 275 0.59, D (m, 2 H), 5.24 (s, 2 H), 65.68 (s, 2

H), 6.78 (t, J=5.8 Hz, 1 H), 7.46 (s, 1 H), 7.76 (dd, J=8.4, 4.9 Hz, 1 H), 7.93 (dd,J=8.5, 1.5 Hz, 1 H), 9.21 (dd,J=5.0, 1.5 Hz, 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.0 Hz, 3 H), 1.15 - 1.34 (m, 4 H), 1.36- 1.50 (m, 1 H), 1.51 - 1.64 (m, lH),2.11(s, 3

334.21 335 0.7, D H), 3.39 - 3.46 (m, 26 H), 3.73 (s,

3 H), 4.02 (td,J=8.8, 4.8 Hz, 1 H), 4.66 (br. s., 1 H), 4.94 (s, 2 H), 5.56 (s, 2 H), 5.85 (d,J=8.8Hz, 1 H), 6.09 (s, 1 H), 7.43 (s, 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.84 (t, J=6.9 Hz, 3 H), 1.14 - 1.34 (m, 4 H), 1.37 - 1.51 (m, 1 H), 1.52 - 1.67 (m, 1 H), 3.36 - 3.48 (m, 2 H), 3.99 -64.11 (m, 1

360.19 361 0.63, D

H),4.69 (br. s., 1 H),5.10 (s, 2 H), 5.54 (s, 2 H), 6.00 (d,J=8.8Hz, 1 H),7.46 (s, 1 H), 7.68 (br. s., 1 H), 7.72 (dd,J=7.3, 1.3 Hz, 1 H), 7.93 - 8.02 (m, 2 H), 8.03 (s, 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.84 (t,J=7.2 Hz, 3 H), 1.11- 1.37 (m, 4 H), 1.47 - 1.63 (m, 2 H), 1.63 - 1.79 (m, 2 H), 2.13 (s, 3 H), 3.40 (t, J=6.3 Hz, 62 H), 3.75

348.23 349 0.73, D

(s, 3H), 4.30(m,J=8.0Hz, 1 H), 5.08 (s, 2 H), 6.21 (s, 1 H), 7.48 (br. s., 2 H), 7.55 (d,J=5.3 Hz, 1 H), 8.11 (d, J=8.8 Hz, 1 H), 11.96 (d,J=5.3 Hz, 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.77- 0.91 (m, 3 H) 1.17- 1.37 (m, 4 H) 1.75 - 1.91 (m, 2 H) 1.93- 2.09 (m, 2 H) 2.74 (t,

372.22 373 1.15, D J=7.65 Hz, 2 H) 3.63 (s, 3 H) 3.87

(q, J=6.02 Hz, 2 H) 4.58 (q, J=7.28 Hz, 1 H) 5.71 (br. s 2 H) 6.53 (d, J=8.28 Hz, 1H) 7.15 -7.35 (m, 5 H) 7.43 (br. s., 1 H) δ

2 (dd, 2 H), 1 (s, 1 δ 1.20 2 (dd, 4.44 1 H) 1 H)

δ 2 H) 2 H) 1 δ 1.19 1 3.90 s., Hz, (d, δ 2 (dd, 3 H), 2 H), H), 1 δ

0.99 (m, H) 1.77 3.90 (d, J=1.00, (s, 2 H), 5.23 1 - 2 (q, 5.9 1 H), δ 1.37 - 1 1 H), 3.68 4.66 1 H), (s, 1 δ 6 H), 4.8 (s, 7.35 (t, 2 - 3 H), (m, 2 LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

H), 7.45 (s, 1H), 7.86- 7.98 (m, 2 H) Η NMR (300 MHz, METHANOL- d ) δ ppm 0.84 (t, J=7.3 Hz, 3 H), 1.17 - 1.33 (m, 2 H), 1.36- 1.52

290.15 291 1.67, E (m, 2H), 3.26 (t, J=7.1 Hz, 2 H),

4.86 (s, 2 H), 6.94 - 7.05 (m, 2 H), 7.17 (s, 1 H), 7.29- 7.40 (m, 2 H), 3 labile protons not seen.

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.88 (t, J=7.0 Hz, 3 H), 1.21 - 1.36 (m, 4 H), 1.46 - 1.51 (m, 2 H), 1.52 (d,J=6.5 Hz, 3 H), 3.22-

300.20 301 1.09, D 3.29 (m, 2 H), 5.17 (q, J=6.3 Hz, 1

H), 5.41 (s, 2 H), 6.34 (t, J=5.9 Hz, 1 H), 7.20 (s, 1 H), 7.23 - 7.29 (m, 1 H), 7.29 -7.36 (m, 2 H), 7.38- 7.44 (m, 2 H)

Η NMR (400 MHz,

CHLOROFORM- d) δ ppm 1.68-

1 1.87 (m, 4 H), 3.46 (q, J=6.5 Hz, 2

214.12 215 0.53, D H), 3.77 (s, 2H), 4.43 (br. s, 2 H),

4.38 - 4.48 (m, 1 H), 4.55 (t, J=5.9 Hz, 1 H), 5.19 (br. s., 1 H), 7.37 (s, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.90 (t, J=7.4 Hz, 3 H), 1.29 (dq,J=14.9, 7.3 Hz, 2 H), 1.45- 1.50 (m, 2 H), 1.52 (d, J=6.5 Hz, 3

286.18 287 0.96, D H), 3.23 - 3.30 (m, 2 H), 5.16 (q,

J=6.4 Hz, 1 H), 5.41 (s, 2 H), 6.33 (t,J=5.9 Hz, 1 H), 7.20 (s, 1 H), 7.23- 7.29 (m, 1 H), 7.29-7.36

(m, 2 H), 7.37 - 7.44 (m, 2 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.90 (t, J=7.4 Hz, 3 H), 1.29 (dq,J=15.0, 7.3 Hz, 2 H), 1.44- 1.50 (m, 2 H), 1.52 (d, J=6.3 Hz, 3

286.18 287 0.97, D H), 3.23 - 3.29 (m, 2 H), 5.17 (q,

J=6.3 Hz, 1 H), 5.42 (s, 2 H), 6.35 (t,J=5.9 Hz, 1 H), 7.20 (s, 1 H), 7.22- 7.29 (m, 1 H), 7.29-7.36

(m, 2 H), 7.38 - 7.44 (m, 2 H) LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

Η NMR (300 MHz,

CHLOROFORM- d) δ ppm 0.95 (t, J=7.3 Hz, 3 H), 1.32- 1.48 (m, 2 H), 1.51 - 1.61 (m, 2 H), 1.62- 1.73 (m, l H), 1.88 - 1.98 (m, 2

266.17 267 1.4, E

H), 1.98 - 2.10 (m, 1 H), 3.38 (td, 1=7.0, 5.8 Hz, 2 H), 3.73 - 3.81 (m, 1 H), 3.82 - 3.95 (m, 3 H), 4.13- 4.27 (m, 1 H), 4.73 (br. s., 2 H), 5.84 (br. s., 1 H), 7.42 (s, 1 H) Η NMR (300 MHz,

CHLOROFORM- d) δ ppm 0.89 J=7.4 Hz, 3 H), 1.26- 1.43 (m, 2 y H), 1.47 - 1.61 (m, 2 H), 3.35 (td,

1=7.0, 5.8 Hz, 2 H), 4.53 (br. s., 2

273.16 274 1.28, F

H),4.97 (s, 2 H), 5.91 (br. s., 1 H), 7.16- 7.24 (m, 1 H), 7.30 (d, J=7.8 Hz, 1 H), 7.38 (s, 1 H), 7.66 (td,J=7.7, 1.6 Hz, 1 H), 8.55 (d, J=4.7 Hz, 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.88 (t, =7.3 Hz, 3 H), 1.26 (dq, J =14.8, 7.3 Hz, 2 H), 1.38- 1.50 (m, 2 H), 1.82 (d, J =7.3 Hz, y 3 H), 3.12- 3.29 (m, 2 H), 4.63 (d,

J =12.5 Hz, 1 H),4.87 (d, J =12.9

366.22 367 0.83, D

Hz, l H),5.51 (s, 2 H), 5.58 (q, J =6.9 Hz, 1 H), 6.08 (t, J =5.9 Hz, 1 H), 7.01 (s, 1 H), 7.12- 7.18 (m, 2 H), 7.25 - 7.30 (m, 1 H), 7.27 (s, 1 H), 7.30 - 7.37 (m, 2 H), 7.97 (s, 1 H)

^X H NMR (300 MHz,

CHLOROFORM-d) δ ppm 0.82 (t, J=7.3 Hz, 3 H), 1.18- 1.33 (m, 2 H), 1.38- 1.51 (m, 2 H), 3.22 -

376.19 377 2.52, F 3.34 (m, 2 H),4.50 (br. s., 2 H),

4.92 (s, 2 H), 5.05- 5.15 (m, 1 H), 7.13 (s, 1 H), 7.32 -7.41 (m, 4 H), 7.43- 7.52 (m, 1 H), 7.63- 7.74 (m, 4 H)

^X H NMR (300 MHz,

CHLOROFORM- d) δ ppm 0.89 (td,J=7.4, 5.0 Hz, 6 H), 1.20 (s, 3 H), 1.25 - 1.39 (m, 2 H), 1.44-

268.19 269 1.74, F

1.62 (m, 4 H), 1.81 - 2.20 (m, 1 H),3.33 (td, J=7.0, 5.8 Hz, 2 H), 3.60 - 3.69 (m, 2 H), 4.55 (br. s., 2 H),5.40 (br. s., 1 H),7.19 (s, 1 H) - 1.28 - 2 H), s., 2 (s, 1 ) δ 1.15 - 2 (m, 1 (s, 3 (s, 1 H) 0.97 (t, 2 - Hz, 2 (t, H), (m, 2 (s, 1 0.89 2 2 (t, H), (m, 1 (d, 0.83 - 2 2 H), (br. s., LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.86 (t, J=7.40 Hz, 3 H) 1.19 - 1.31 (m, 2 H) 1.37 - 1.48 (m, 2

126 H) 3.20 - 3.27 (m, 2 H) 4.13 - 4.23

327.17 328 0.84, D

(m, 2 H) 4.30 - 4.42 (m, 2 H) 5.57 (s, 2 H) 6.22 (s, 1 H) 7.12 -7.20 (m, 2 H) 7.45 (s, 1 H) 7.75 - 7.83 (m, 2 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.80- 0.91 (m, 3 H) 1.20- 1.32 (m, 2 H) 1.37 - 1.50 (m, 2 H) 3.17- 3.28 (m, 2 H) 3.73 (s, 3 H)

127

ffS 332.18 333 0.94, D 4.13 (dd,J=5.52, 3.26 Hz, 2 H)

4.23 (dd,J=5.52, 3.26 Hz, 2 H) 5.56 (s, 2 H) 6.20 (s, 1 H) 6.49 - 6.59 (m, 3 H) 7.16 -7.22 (m, 1 H) 7.45 (s, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.76 (t, J=7.28 Hz, 3 H) 1.11 - 1.21 (m, 2 H) 1.32 (t, J=7.15 Hz, 2 H) 3.15 - 3.22 (m, 2 H) 4.32- 4.36 (m, 2 H) 4.52 - 4.56 (m, 2 H)

128

353.19 354 0.79, D 5.57 (s, 2 H) 6.24 (s, 1 H) 7.07 (d,

J=5.27 Hz, 1 H) 7.55 (s, 1 H) 7.52 -

7.58 (m, 1 H) 7.74 (ddd, J=8.41, 6.90, 1.25 Hz, 1 H) 7.95 (d, J=8.03 Hz, 1 H) 8.12 (dd, J=8.28, 1.00 Hz, 1 H) 8.73 (d,J=5.27 Hz, 1 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.78- 0.93 (m, 3 H) 1.12- . k 1.35 (m, 2 H) 1.39 - 1.54 (m, 2 H)

129 3.18 - 3.28 (m, 2 H) 4.07 -4.17

362.20 363 0.92, D

(m, 2 H)4.21 (dd,J=5.52, 3.01 Hz, 2 H)5.58(br. s., 2 H) 6.09 - 6.12 (m, 1 H) 6.14 (d, J=2.26 Hz, 2 H) 6.21 (s, 1 H) 7.45 (s, 1 H)

^X H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.86 (t, J=7.28 Hz, 3 H) 1.20 - 1.31 (m, 2 H) 1.39 - 1.48 (m, 2 H) 3.21- 3.28 (m, 2 H) 3.67 (s, 3

130

ΐίΎ ^ΝΗ 362.20 363 0.87, D H)3.77 (s, 3 H) 4.11 -4.18 (m, 2

H) 4.22- 4.29 (m, 2 H) 5.56 (s, 2 H)6.18 (t, J=5.90 Hz, 1 H) 6.66 - 6.74 (m, 2 H) 6.96 -7.01 (m, 1 H) 7.47 (s, 1 H) LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.28 Hz, 3 H) 1.18 - 1.30 (m, 2 H) 1.36- 1.47 (m, 2 H) 3.17 - 3.28 (m, 2 H) 4.12 - 4.22

131

370.16 371 1.05, D (m, 2 H) 4.33 - 4.43 (m, 2 H) 5.61

(s, 2 H) 5.98 (s, 1 H) 7.09 -7.15 (m, 1 H) 7.33 (d, J=8.53 Hz, 1 H) 7.47 (s, 1 H) 7.63 (d, J=7.78 Hz, 2 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.28 Hz, 3 H) 1.19

- 1.32 (m, 2 H) 1.37 - 1.49 (m, 2 H) 3.17- 3.28 (m, 2 H) 3.83 (s, 3

132 H)3.82(s, 3 H)4.16(dd,J=5.27,

390.19 391 0.86, D

3.26 Hz, 2 H) 4.32 (dd,J=5.27, 3.26 Hz, 2 H) 5.59 (s, 2 H) 6.18 (s, 1 H)7.14(d,J=8.53 Hz, 1 H) 7.45

- 7.53 (m, 2 H) 7.59 (dd, J=8.53, 2.01 Hz, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.86 (t, J=7.40 Hz, 3 H) 1.20 - 1.34 (m, 2 H) 1.40 - 1.52 (m, 2

133 H) 3.14- 3.28 (m, 2 H) 3.58 (s, 3

392.21 393 0.84, D

H)3.75(s, 6H)4.13(dd,J=5.52, 3.26 Hz, 2 H) 4.23 (dd, J=5.52, 3.01 Hz, 2 H) 5.58 (s, 2 H) 6.22 (s,

1 H) 6.28 (s, 2 H) 7.46 (s, 1 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.40 Hz, 3 H) 1.20 - 1.30 (m, 2 H) 1.39 - 1.48 (m, 2 H) 3.20- 3.28 (m, 2 H) 3.73 (s, 3

134 H)3.81 (s, 3 H) 4.13 -4.19 (m, 2

390.19 391 0.83, D

H) 4.34 (dd, J=5.27, 3.26 Hz, 2 H) 5.56 (s, 2 H) 6.20 (s, 1 H) 6.63 (dd, J=8.66, 2.38 Hz, 1 H) 6.68 (d, J=2.26 Hz, 1 H) 7.46 (s, 1 H) 7.71 (d,J=8.53 Hz, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.40 Hz, 3 H) 1.18 - 1.34 (m, 2 H) 1.36 - 1.47 (m, 2

135 H) 3.17 - 3.27 (m, 2 H) 4.13 - 4.23

370.16 371 1.06, D

(m, 2 H) 4.29 - 4.41 (m, 2 H) 5.57 (s, 2 H) 6.21 (s, 1 H) 7.17 (m, J=8.53 Hz, 2 H) 7.46 (s, 1 H) 7.67 (m, J=8.53 Hz, 2 H) δ

1.16 2 - 4.28 5.57 7.53 J=5.52 1 H) δ 1.22 2 (s, 3 5.50 7.28 - δ 1.20 2 - 3.32 4.89 1 H) δ 1.22 2 2 (s, 2 1 H) δ 1.18 2 (s, 3 2 (s, 2 Hz, 1 7.45 (s, δ 1.12 2 (s, 3 2 H) Hz, 1 LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm0.91(t,J=7.3 Hz, 3 H), 1.30 (dq,J=14.9, 7.4 Hz, 2 H), 1.55 (quin,J=7.3 Hz, 2 H), 1.97-2.08 (m, 2 H), 2.69 - 2.78 (m, 62 H),

146

330.21 331 1.03, D 3.42 (q, J=6.8 Hz, 2 H), 3.73 (s, 3

H), 3.90 (t,J=6.3 Hz, 2 H), 6.73- 6.78 (m, 1 H), 6.78 - 6.83 (m, 2 H), 7.17 -7.25 (m, 1H), 7.37 (s, 1 H), 7.43 (br. s., 2 H), 8.32 (t, J=6.0 Hz, 1 H), 11.83 (br. s., 1 H)

¹ H NMR (400 MHz,

CHLOROFORM-d) δ ppm 0.90 (t, J=7.4Hz, 3H), 1.24- 1.37 (m, 2 H), 1.55 (t,J=7.3 Hz, 2 H), 1.96-

147 2.07 (m, 2 H), 2.65 - 2.74 (m, 2

360.22 361 1.02, D

H),3.42 (q,J=6.9Hz, 2 H), 3.71 (s, 6 H), 3.89 (t, J=6.1 Hz, 2 H), 6.31 - 6.35 (m, 1 H), 6.38 (d, J=2.3 Hz, 2 H), 7.34 (s, 1 H), 7.39 (br. s., 2 H), 8.31 (s, 1 H)

^ NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.90 (t, J=7.4 Hz, 3 H), 1.23 - 1.36 (m, 2 H), 1.49 - 1.60 (m, 2 H), 1.92 - 2.04 (m, 2 H), 2.68 (t, J=7.5 Hz, 2 H), 3.41 (q, 6 J=6.8 Hz,

148

360.22 361 1.03, D 2 H), 3.67 (s, 3 H), 3.71 (s, 3 H),

3.89 (t, J=6.3 Hz, 2 H), 6.69 - 6.77 (m, 2H), 6.84 - 6.91 (m, 1 H), 7.34 (s, 1 H), 7.41 (br. s., 2 H), 8.31 (t, J=5.9 Hz, 1 H), 11.70 (s, 1 H)

^X H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.90 (t, J=7.4 Hz, 3 H), 1.24 - 1.37 (m, 2 H), 1.49 - 1.61 (m, 2 H), 1.92- 2.05 (m, 2 H), 2.67- 2.76 (m, 2 H), 3.41 (q, 6 J=6.9 Hz,

149 a! 330.21 331 1.06, D 2 H), 3.76 (s, 3 H), 3.90 (t,J=6.3

Hz, 2 H), 6.87 (td, J=7.4, 1.0 Hz, 1 H), 6.96 (d, J=7.5 Hz, 1 H), 7.11- 7.23 (m, 2H), 7.33 (s, 1 H), 7.40 (br. s., 2 H),8.31 (t,J=5.9 Hz, 1 H), 11.67 (br. s., 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ 1 ppm 0.90 (t, J=7.4 Hz, 3 H), 1.24 - 1.36 (m, 2 H), 1.55 (quin, J=7.3

150

360.22 361 1.02, D Hz, 2 H), 1.93 - 2.04 (m, 2 H),

2.69 - 2.76 (m, 2 H), 63.41 (q, J=6.8Hz, 2H), 3.70 (s, 3 H), 3.78 (s, 3H), 3.91(t,J=6.4 Hz, 2 H), LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

J=8.5 Hz, 1 H), 7.38 (s, 1 H), 7.46 (br. s., 2H), 8.30 (t,J=5.9 Hz, 1 H), 11.94 (br. s., 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.40 Hz, 3 H) 1.21

- 1.34 (m, 2 H) 1.41 - 1.57 (m, 2 — H) 1.57 - 1.70 (m, 2 H) 1.94 - 2.01

165 (m, 2 H) 2.69- 2.75 (m, 2 H) 3.38

344.22 345 0.97, D

- 3.46 (m, 2 H) 3.82 (td, J=6.34, 1.88 Hz, 2 H) 4.11 -4.18 (m, 1 H) 4.45 (t, J=5.02 Hz, 1 H) 5.48 (s, 2 H) 6.00 (d, J=8.78 Hz, 1H)7.11- 7.31 (m, 5 H) 7.33 (s, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.90 (t, J=7.40 Hz, 3 H) 1.02 - 1.14(m, 2H) 1.23 - 1.38 (m, 2 H) 1.46 - 1.59 (m, 2 H) 3.36 - 3.46

166 (m, 2 H) 5.13 (s, 2 H) 5.55 (s, 2 H)

323.17 324 5.32, G

6.79 (br. s., 1 H) 7.48 (s, 1 H) 7.70 (ddd, J=8.16, 6.90, 1.00 Hz, 1 H) 7.78- 7.85 (m, 1 H) 8.00 (d, J=1.00 Hz, 1 H) 7.99 (s, 1 H) 8.16 (d,J=7.53 Hz, 1 H) 9.34 (s, 1 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.92 (t, J=7.3 Hz, 3 H), 1.27 - y 1.38 (m, 2 H), 1.51 - 1.63 (m, 2

H), 3.40 -3.48 (m, 2 H), 3.78 (t,

167

376.23 377 1.18, D J=6.1 Hz, 2 H), 4.32 (t, J=8.0 Hz, 1

H), 7.13 -7.22 (m, 2 H), 7.25- 7.36 (m, 10 H), 7.49 (br. s., 2 H), 8.33 (t, J=6.0 Hz, 1 H), 12.01 (s, 1 H).214

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.87 (t, J=7.3 Hz, 3 H), 1.12 (d,J=6.8 Hz, 3 H), 1.19- 1.31 (m, 2 H), 1.39- 1.50 (m, 1 H), 1.52-

168

300.20 301 1.06, D 1.64 (m, 1 H), 2.03 (s, 3 H), 4.07 - (br. s., 2H), 4.15 - 4.27 (m, 1 H),

4.78-4.91 (m, 2 H), 7.35-7.43 (m, 3H), 7.44- 7.48 (m, 2 H), 7.92 (d, J=8.8 Hz, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.91 (t,J=7.3 Hz, 3 H), 1.31 (dq,J=14.9, 7.4 Hz, 2 H), 1.55 (quin,J=7.3 Hz, 2 H), 1.96-2.09

169

368.12 369 1.19, D (m, 2H), 2.74- 2.83 (m, 62 H),

3.42 (q, J=6.8 Hz, 2 H), 3.90 (t, J=6.1 Hz, 2 H), 7.25 (dd, J=8.3, 2.0 Hz, 1 H), 7.38 (s, 1 H), 7.44 (br. s., 1 H), 7.53 (d, J=2.0 Hz, 1 H), 7.55 LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

Hz, 1 H), 9.04 (dd, J=4.3, 1.8 Hz, 1 H), 12.01 (d, J=4.8 Hz, 1 H)

¹ H NM R (400 MHz,

CHLOROFORM- d) δ ppm 0.89 (t, J=7.3 Hz, 3 H), 1.21 (d, J=6.5 Hz, 3 H), 1.28 - 1.40 (m, 2 H), 1.43 - 1.62 (m, 2 H), 3.45 (s, 2 H), 4.23 (dd, J=7.9, 7.2 Hz, 1 H), 5.29 (s, 2

337.19 338 0.95, D

H), 6.70 (d, J=8.5 Hz, 1 H), 7.40 (s, 1 H), 7.54 (d, J=8.5 Hz, 1 H), 7.56 - 7.60 (m, 1 H), 7.74 (ddd, J=8.5, 7.0, 1.4 Hz, 1 H), 7.85 (dd, J=8.0, 1.0 Hz, 1 H), 8.08 (d, J=8.5 Hz, 1 H), 8.22 (d, J=8.3 Hz, 1 H)

¹ H NM R (400 MHz,

CHLOROFORM- d) δ ppm 0.80 - 0.89 (m, 3 H), 1.20 - 1.35 (m, 5 H), 1.44 (d, J=3.5 Hz, 1 H), 1.59 (dd, J=8.3, 5.8 Hz, 2 H), 1.86 - 1.98 (m, 1 H), 3.11 - 3.40 (m, 2 H), 3.55 (dd, J=10.8, 3.0 Hz, 1 H), 3.59 (dd, J=5.0, 3.3 Hz, 1 H), 4.14

381.22 382 0.9, D

- 4.27 (m, 1 H), 5.25 (s, 2 H), 6.32 (d, J=8.8 Hz, 1 H), 7.46 (s, 1 H), 7.48 (d, J=8.5 Hz, 1 H), 7.57 (ddd, J=8.1, 7.0, 1.3 Hz, 1 H), 7.75 (ddd, J=8.5, 7.0, 1.4 Hz, 1 H), 7.84 (d, J=8.3 Hz, 1 H), 8.07 (d, J=8.5 Hz, 1 H), 8.21 (d, J=8.5 Hz, 1 H) taken on the free base

¹ H NM R (400 M Hz, DMSO-d ₆ ) δ ppm 0.87 (t, J=7.3 Hz, 3 H), 1.21 - 1.36 (m, 2 H), 1.47 - 1.63 (m, 1 H), 1.69 - 1.88 (m, 2 H), 1.89 - 2.04 (m, 1 H), 2.29 (s, 3 6 H), 2.43

375.23 376 0.81, D (s, 3 H), 3.41 (t, J=6.5 Hz, 2 H),

4.03 (s, 3 H), 4.36 - 4.50 (m, 1 H), 5.41 (s, 2 H), 7.53 (br. s., 2 H), 7.86 (d, J=5.5 Hz, 1 H), 8.62 (s, 1 H), 9.19 (d, J=8.8 Hz, 1 H), 12.35 (d, J=5.3 Hz, 1 H)

¹ H NM R (400 MHz,

CHLOROFORM- d) δ ppm 0.85 (t, J=7.40 Hz, 3 H) 1.25 - 1.43 (m, 3 H) 1.50 - 1.59 (m, 2 H) 1.82 - 1.94

367.20 368 0.78, H

(m, 1 H) 2.92 - 3.32 (m, 1 H) 3.42 - 3.51 (m, 1 H) 3.53 - 3.60 (m, 1 H) 4.11 - 4.23 (m, 1 H) 4.83 (s, 2 H) 5.22 (s, 2 H) 5.73 (d, J=8.78 Hz, LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

1 H)7.46(d,J=8.53 Hz, 1 H) 7.53 (s, 1 H) 7.55- 7.59 (m, 1 H) 7.73 (ddd, J=8.47, 6.96, 1.38 Hz, 1 H) 7.82 (d, J=8.03 Hz, 1 H) 8.08 (d, J=8.28 Hz, 1 H) 8.18 (d, J=8.53 Hz, 1 H)

Η NMR (400 MHz, DMSO-d ₅ ) δ ppm 0.79- 0.87 (m, 3 H), 1.15-

I.21 (m, 4 H), 1.22 - 1.28 (m, 6 H), 4.16- 4.40 (m, 1 H), 5.35 - 5.40 (m, 2 H), 7.40 - 7.48 (m, 2

365.22 366 1.13, D H), 7.50 -7.54 (m, 1H), 7.62- 7.68 (m, 1 H), 7.73 -7.77 (m, 1 H), 7.78 - 7.85 (m, 1 H), 7.99 - 8.07 (m, 2 H), 8.31 - 8.38 (m, 1 H), 8.45-8.51 (m, 1 H), 11.47 -

II.58 (m, 1 H)

^: H NMR (300 MHz,

CHLOROFORM- d) δ ppm 0.84 (t, J=7.4Hz, 3H), 1.14-1.55 (m, 6 H), 1.75- 1.90 (m, 1 H), 3.30-

316.19 317 0.84, D 3.43 (m, 1 H), 3.45 -3.57 (m, 1

H), 4.06 (ddd, J=11.3, 5.2, 3.3 Hz, 1 H), 4.42 (s, 2 H), 4.80 - 4.86 (m, 1 H), 4.90 (s, 2 H), 7.27 -7.34 (m,

5 H), 7.40 (s, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.89 (t, J=7.28 Hz, 3 H) 1.12 y— -1.40(m, 2H) 1.43 - 1.60 (m, 2

H)2.68 (s, 3 H) 3.32 -3.48 (m, 2

293.13 294 0.71, D

H) 5.07 (s, 2 H) 7.57 (br. s., 2 H) 7.61 (br. s., 1 H) 7.78 (s, 1 H) 8.45 (t,J=5.90 Hz, 1 H) 12.21 (br. s., 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.87 (t, J=7.4 Hz, 3 H), 1.16 - 1.35 (m, 2 H), 1.51 - 1.63 (m, 2 H), 3.48- 3.55 (m, 2 H), 4.28 (d, J=6.0 Hz, 1H), 5.41 (s, 2 H), 7.51 (br. s., 2H), 7.58 (d, J=5.5 Hz, 1

353.19 354 0.78, D H), 7.68 (td,J=7.5, 1.0 Hz, 1 H),

7.79 (d, J=8.5 Hz, 1 H), 7.85 (ddd, J=8.5, 7.0, 1.4 Hz, 1 H), 8.07 (d, J=7.3 Hz, 1 H), 8.11 (d, J=8.5 Hz, 1

H), 8.18 (d, J=9.0 Hz, 1 H), 8.55 (d,J=8.5 Hz, 1 H), 11.83 (d, J=5.5 Hz, 1 H) LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

1 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.77- 0.84 (m, 3 H), 1.14-

1.34 (m, 5 H), 1.48 (d, J=5.8 Hz, 2 H), 1.56- 1.67 (m, 1 H), 3.39- 3.51 (m, 2 H), 4.07 (d, J=5.0 Hz, 1 H),4.72 (br. s., 1 H), 5.63 (s, 2 H),

367.20 368 0.85, D

6.35 (d, J=9.0 Hz, 1 H), 7.47 (s, 1 H), 7.62 (ddd, J=8.1, 6.8, 1.1 Hz, 1 H), 7.69 (d, J=8.5 Hz, 1 H), 7.79 (ddd, J=8.4, 6.9, 1.5 Hz, 1 H), 7.98 - 8.05 (m, 2 H), 8.41 (d, J=8.5 Hz, 1 H)

Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.88- 0.94 (m, 3 H), 1.20- y 1.37 (m, 2 H), 1.55 (quin, J=7.3

Hz, 2 H), 3.42 (q, J=6.8 Hz, 2 H),

274.15 275 0.65, D

5.22 (s, 2 H), 7.59 (br. s., 2 H), 7.66 (br. s., 1 H), 8.51 (t, J=5.9 Hz, 1 H), 8.68 (s, 2 H), 9.02 (s, 1 H), 12.24 (br. s., 1 H)

Η NMR (300 MHz,

CHLOROFORM-d) δ ppm 0.96 J=7.2Hz, 3H), 1.36- 1.50 (m, 3 H), 1.50- 1.69 (m, 3 H), 2.00- 2.14 (m, 2 H), 2.72 (t, J=7.4 Hz, 2 — 360.22 361 2.21, F H), 3.58 -3.66 (m, 1 H), 3.80 (s, 3

H), 3.91 (t, J=6.3 Hz, 2 H), 4.05 (d, J=5.9Hz, 1H), 4.59 (br. s., 2 H), 5.25 (d, J=6.9 Hz, 1 H), 6.80 - 6.88 (m, 2 H), 7.11 (d, J=8.5 Hz, 2 H), 7.34 (s, 1 H)

^X H NMR (300 MHz,

CHLOROFORM-d) δ ppm 0.85 - 0.96 (m, 3 H), 1.23 - 1.43 (m, 5 H), 1.46- 1.71 (m, 2 H), 1.99- 2.13 (m, 2 H), 2.71 (t, J=7.5 Hz, 2 H), 3.57 - 3.66 (m, 1 H), 3.74 (d,

374.23 375 2.43, F

J=3.2Hz, 1H), 3.78 (s, 3 H), 3.90 (t,J=6.3 Hz, 2 H), 4.03 (t,J=5.5 Hz, 1 H), 4.63 (br. s., 2 H), 5.26 (d,J=7.1 Hz, 1 H), 6.80- 6.89 (m, 2 H), 7.10 (d, J=8.5 Hz, 2 H), 7.32 (s, 1 H) LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

H NMR (300 MHz,

CHLOROFORM-d) δ ppm 0.94 (t, J=7.3Hz, 3H), 1.32- 1.52 (m, 3 H), 1.53- 1.68 (m, 2 H), 2.59 (s, 3 H), 3.58 - 3.68 (m, 1 H), 3.74- Y 317.19 318 1.35, F

3.84 (m, 1 H), 4.12 (td, J=6.9, 3.0 Hz, 1 H),4.61 (br. s., 2 H), 4.99 (s, 2 H), 5.94 (d, J=7.1 Hz, 1 H), 7.15 (dd,J=11.7, 7.7 Hz, 2 H), 7.49 (s, 1 H), 7.62 (t, J=7.7 Hz, 1 H) H NMR (300 MHz,

CHLOROFORM-d) δ ppm 0.85 - 0.96 (m, 3 H), 1.18 - 1.46 (m, 5 H), 1.50- 1.72 (m, 2 H), 2.59 (s, 3 H), 3.58 - 3.69 (m, 1 H), 3.75-

331.20 332 1.63, F

3.84 (m, 1 H), 4.09 (td, J=6.9, 2.6 Hz, 1 H), 4.62 (br. s., 2 H), 5.00 (s, 2 H), 5.95 (d, J=7.0 Hz, 1 H), 7.15 (dd,J=12.3, 7.8 Hz, 2 H), 7.49 (s, 1 H), 7.62 (t, J=7.7 Hz, 1 H) H NMR (300 MHz,

CHLOROFORM-d) δ ppm 0.97 (t, J=7.2Hz, 3H), 1.32- 1.49 (m, 3 H), 1.51 - 1.70 (m, 3 H), 1.98- 2.14 (m, 2 H), 2.70 (t,J=7.5 Hz, 1 H), 3.59 - 3.71 (m, 1 H), 3.74 -

374.20 375 2.26, F

3.83 (m, 1 H), 3.91 (t, J=6.4 Hz, 1

H H), 3.99 -4.15 (m, 1H), 4.68 (br.

s., 2 H), 5.26 - 5.33 (m, 2 H), 5.92 -5.95(m, 2H), 6.59 - 6.66 (m, 1 H), 6.69 (d,J=1.4 Hz, 1 H), 6.72- 6.78 (m, 1 H), 7.33 (s, 1 H) H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.84 (t, J=7.28 Hz, 3 H) 1.15 - 1.30 (m, 2 H) 1.43 - 1.57 (m, 1 H) 1.57 - 1.69 (m, 1H) 1.69-1.87 (m, 2 H) 3.37 - 3.45 (m, 2 H) 4.24

356.20 357 0.66, D -4.43(m, 1 H)5.30 (s, 2 H) 7.28

(t,J=6.53 Hz, 1 H) 7.55 (br. s., 2

O H)7.70 (s, 1 H) 7.62 - 7.77 (m, 1

H) 7.81 (d, J=8.78 Hz, 1 H) 8.31 (s, 1 H) 8.27 - 8.35 (m, 1 H) 8.81 (d, J=6.78 Hz, 1 H) 12.15 (br. s., 1 H) H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.89 (t, J=7.40 Hz, 3 H) 1.15 - 1.33 (m, 2 H) 1.35 (s, 3 H) 1.43-

266.17 267 0.72, D 1.56 (m, 2 H) 3.12 -3.30 (m, 2 H)

3.91 (s, 2 H) 4.28 (d, J=5.77 Hz, 2 H) 4.46 (d, J=5.77 Hz, 2 H) 5.50 (s, 2 H) 6.20 (t,J=5.90 Hz, 1 H) 7.41 δ

1.13 (m, 1 - 1.89 4.27 7.47 7.73 2 H) (s, 1 12.19 δ 1.13 1 - 2.00 4.42 H) H) 7.96 1 H) 8.64 s., 1 δ 1.29 (dd, (s, 2 1 H), H), 1 H), (d, 1 H) δ 1.22 - 2 (s, 2 (m, 12.17 LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

¹ H NMR (300 MHz,

CHLOROFORM δ ppm 0.74 - 0.88 (m, 3 H), 1.14 - 1.36 (m, 4 H), 1.40 - 1.65 (m, 2 H), 1.77 - 1.93 (m, 2 H), 2.00 (quin, J=6.9 Hz, 2 H), 2.64 (td,J=7.4,2.4 Hz, 2

225 H), 3.38 - 3.42 (m, 1 H), 3.46 (dd,

388.25 389 2.51, F

J=11.4, 2.6 Hz, 1 H), 3.52 (dd, J=5.1, 2.2 Hz, 1 H), 3.72 (s, 3 H), 3.84 (td, J=6.3, 1.8 Hz, 2 H), 4.06 (d,J=2.7 Hz, 1H), 4.48 (br. s., 2 H),4.89 (d,J=8.7 Hz, 1 H), 6.72- 6.80 (m, 2 H), 7.02 (d, J=8.7 Hz, 2 H),7.25(s, 1H)

¹ H NMR (300 MHz,

CHLOROFORM δ ppm 0.85 J=7.2Hz, 3H), 1.24- 1.39 (m, 3

NH ₂ H), 1.41 - 1.54 (m, 2 H), 1.85 (d, VNH J=5.4 Hz, 1 H), 2.00 (t, J=6.9 Hz, 2

H), 2.64 (td,J=7.4, 2.1Hz, 2 H),

226

374.23 375 2.36, F 3.42 (s, 1 H), 3.46 (dd, J=11.4, 2.6

Hz, 1 H), 3.52 (d,J=2.6Hz, 1 H), 3.72 (s, 3 H), 3.84 (td, J=6.4, 1.4

I Hz, 2 H), 4.01 - 4.17 (m, 1 H),

4.46 (br. s., 2 H), 4.85 (br. s., 1 H), 6.71 - 6.82 (m, 2 H), 6.97-7.08 (m, 2 H), 7.26 (s, 1 H)

¹ H NMR (300 MHz,

CHLOROFORM δ ppm 0.90 (t, J=7.3 Hz, 3 H), 1.22- 1.50 (m, 4 H), 1.52 - 1.67 (m, 2 H), 1.83- 2.05 (m, 1 H), 2.58 (s, 3 H), 3.43 -

227

331.20 332 1.5, F 3.55 (m, 1 H), 3.56 -3.65 (m, 1

H),4.20(br. s., 1 H), 4.60-4.76 (m, 2H), 4.99 (s, 2 H), 5.82 (d, J=8.7 Hz, 1 H), 7.14 (t, J=6.8 Hz, 2 H), 7.50 (s, 1 H), 7.61 (t, J=7.7 Hz, 1 H)

¹ H NMR (300 MHz,

CHLOROFORM δ ppm 0.92 (t, J=1.0Hz, 3H), 1.22- 1.43 (m, 5 H), 1.47 - 1.71 (m, 2 H), 1.97 - 2.12 (m, 2 H), 2.64 - 2.75 (m, 2

228 H), 3.63 (dd, J=10.9, 6.8 Hz, 1 H),

388.21 389 2.4, F

3.74 - 3.83 (m, 1 H), 3.91 (t, J=6.3 Hz, 2 H), 3.97- 4.10 (m, 1 H), 4.57 (br. s., 2 H), 5.26 (d, J=6.7 Hz, 1 H), 5.94 (s, 2 H), 6.59 - 6.66 (m, 1H), 6.69(d,J=1.5 Hz, 1 H), 6.72 - 6.78 (m, 1 H), 7.35 (s, 1 H) LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

8.00 (m, 2 H), 8.36 - 8.46 (m, 2 H),8.93 (d,J=6.5 Hz, 1 H), 12.24 (br. s., 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm0.87 (t,J=7.4 Hz, 3 H), 1.24 (d,J=6.5 Hz, 3 H), 1.25 - 1.33 (m, ά; 2 H), 1.47 - 1.60 (m, 1 H), 1.71- 1.86 (m, 1 H), 3.916 (s, 3 H), 4.12

347.20 348 0.86, D

(s, 3 H), 4.28 - 4.42 (m, 1 H), 5.36 (s, 2 H), 7.57 (br. s, 2 H), 7.63 (d, J=6.5 Hz, 1 H), 7.72 - 7.80 (m, 1 H), 8.56 (d, J=6.5 Hz, 1 H), 8.99 - 9.10 (m, 1 H), 12.27 (br. s., 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm0.85 (t,J=7.4 Hz, 3 H), 1.21 (d,J=6.5 Hz, 3 H), 1.23 - 1.29 (m, 2 H), 1.45 - 1.58 (m, 1 H), 1.66- 1.80 (m, 1 H), 4.21 -64.38 (m, 1

326.19 327 0.79, D

H), 5.33 - 5.45 (m, 2 H), 7.44 - 7.55 (m, 1 H), 7.62 (br. s., 2 H), 7.76 (s, 1 H), 7.89 - 8.02 (m, 2 H), 8.40 - 8.52 (m, 2 H), 8.96 (d, J=6.8 Hz, 1 H), 12.39 (br. s., 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm0.86 (t,J=7.3 Hz, 3 H), 1.17- 1.35 (m, 2 H), 1.36 - 1.47 (m, 1 H), 1.47 - 1.60 (m, 1 H), 2.11 (s, 3

320.20 321 0.62, D H), 3.36 -3.47 (m, 26 H), 3.73 (s,

3 H), 4.05 (td, J=8.8, 4.9 Hz, 1 H), 4.66 (br. s., 1 H), 4.94 (s, 2 H), 5.58 (s, 2 H), 5.86 (d,J=9.0Hz, 1 H), 6.10 (s, 1H), 7.43 (s, 1 H)

^X H NMR (400 MHz, DMSO-d ₆ ) δ

\ ppm 0.84 (t, J=7.0 Hz, 3 H), 1.11 -

I.38 (m, 4 H), 1.39 - 1.67 (m, 2 H), 2.23 (s, 3 H), 3.38- 3.52 (m, 2

334.21 335 0.72, D H), 3.70 (s, 3 H), 64.13 - 4.24 (m,

1 H), 4.93 (s, 2 H), 6.16 (s, 1 H), 7.47 (br. s., 2 H), 7.53 (d,J=5.3 Hz, 1 H), 7.79 (d,J=9.0Hz, 1 H),

II.96 (d,J=5.3 Hz, 1 H)

¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.86 (t, J=7.3 Hz, 3 H), 1.17 - a, 1.33 (m, 2 H), 1.39 - 1.50 (m, 1

H), 1.50 - 1.62 (m, 1 H), 3.37 -

346.18 347 0.55, D 3.48 (m, 2 H), 4.01 - 64.14 (m, 1

H),4.69 (br. s., 1 H),5.10 (s, 2 H), 5.54 (s, 2 H), 6.00 (d,J=9.0Hz, 1 H),7.46 (s, 1 H), 7.68 (br. s., 1 H), 7.72 (dd,J=7.5, 1.3 Hz, 1 H), 7.94 LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

^X W NM R (400 M Hz, DMSO-d ₆ ) δ ppm 0.87 (t, J=7.4 Hz, 3 H), 1.17 -

CI 1.35 (m, 2 H), 1.47 - 1.62 (m, 2

H), 3.43 - 3.54 (m, 2 H), 4.19 - 4.31 (m, 1 H), 5.39 (s, 2 6 H), 7.55

277

304.16 305 0.5, D (br. s., 2 H), 7.65 (d, J=4.0 Hz, 1

H), 7.85 (dd, J=8.5, 5.0 Hz, 1 H), 8.00 (dd, J=8.4, 1.6 Hz, 1 H), 8.07 (d, J=8.8 Hz, 1 H), 9.27 (dd, J=4.9, 1.6 Hz, 1 H), 12.03 - 12.17 (m, 1 H)

W NM R (400 M Hz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.0 Hz, 3 H), 1.14 - 1.38 (m, 4 H), 1.45 - 1.71 (m, 2

OS H), 3.42 - 3.53 (m, 2 H), 4.23 (td,

J=9.0, 5.4 Hz, 1 H), 6 5.39 (s, 2 H),

278

318.18 319 0.58, D 7.55 (br. s., 2 H), 7.65 (d, J=3.3

Hz, 1 H), 7.84 (dd, J=8.4, 4.9 Hz, 1 H), 8.00 (dd, J=8.5, 1.5 Hz, 1 H), 8.07 (d, J=8.8 Hz, 1 H), 9.27 (dd, J=5.0, 1.8 Hz, 1 H), 12.10 (br. s., 1 H)

W NM R (400 M Hz, DMSO-d ₆ ) δ ppm 0.87 (t, J=7.3 Hz, 3 H), 1.25 (dq, J=14.9, 7.4 Hz, 2 H), 1.45 - 1.66 (m, 2 H), 1.66 - 1.83 (m, 2 H), 3.43 (t, J=6.4 Hz, 2 6 H), 4.28 -

279

318.18 319 0.54, D 4.40 (m, 1 H), 5.39 (s, 2 H), 7.56

(br. s., 2 H), 7.66 (d, J=4.0 Hz, 1 H), 7.85 (dd, J=8.5, 5.0 Hz, 1 H), 7.98 (dd, J=8.5, 1.5 Hz, 1 H), 8.26 (d, J=9.0 Hz, 1 H), 9.27 (dd, J=4.9, 1.6 Hz, 1 H), 12.13 (br. s., 1 H)

^X W NM R (400 M Hz, DMSO-d ₆ ) δ ppm 0.85 (t, J=7.0 Hz, 3 H), 1.15 - 1.35 (m, 4 H), 1.49 - 1.66 (m, 2 H), 1.68 - 1.80 (m, 2 H), 3.43 (t, J=6.4 Hz, 2 H), 4.26 - 6 4.39 (m, 1

280

332.20 333 0.62, D H), 5.39 (s, 2 H), 7.55 (br. s., 2 H),

7.66 (d, J=4.3 Hz, 1 H), 7.85 (dd, J=8.5, 5.0 Hz, 1 H), 7.97 (dd, J=8.5, 1.5 Hz, 1 H), 8.26 (d, J=8.8 Hz, 1 H), 9.27 (dd, J=5.0, 1.5 Hz, 1 H), 12.05 - 12.16 (m, 1 H)

^X W NM R (400 M Hz, DMSO-d ₆ ) δ y— ppm 0.89 (t, J=7.3 Hz, 3 H), 1.28

(dq, J=14.9, 7.3 Hz, 2 H), 1.49

281

302.17 303 0.71, D (quin, J=7.3 Hz, 2 H), 3.23 - 3.31

(m, 2 H), 4.49 (br. s., 2 6 H), 4.93 (s, 2 H), 5.17 (br. s., 1 H), 5.47 (s, 2 H), 6.37 (t, J=5.8 Hz, 1 H), 7.26 - LCMS

Mass

Exact Ret

STRUCTURE Found 1H NMR

Mass Time,

[M+H]

Method

7.33 (m, 2 H), 7.33 - 7.42 (m, 3 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.84 (t, J=7.0 Hz, 3 H), 1.13 - 1.33 (m, 4 H), 1.42 - 1.56 (m, 2 H), 1.56 - 1.73 (m, 2 H), 3.40 (br.

282 s., 2 H), 4.06 - 4.20 6 (m, 1 H),

374.21 375 0.66, D

4.44 (br. s., 1 H), 5.10 (s, 2 H), 5.55 (s, 2 H), 6.28 (d, J=8.8 Hz, 1 H), 7.45 (s, 1 H), 7.67 (br. s., 1 H), 7.71 - 7.76 (m, 1 H), 7.93 - 8.03 (m, 2 H), 8.06 (br. s., 1 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.82 J=7.40 Hz, 3 H) 1.11 - 1.22 (m, 2 H) 1.43 - 1.55 (m, 2 H) 1.66 - 1.76 (m, 2 H) 2.25 - 2.34 (m, 1 H) 2.52 - 2.65 (m, 1 H) 2.88

283 - 2.97 (m, 1 H) 3.10 - 3.22 (m, 1

377.16 378 0.91, D

H) 3.43 (t, J=6.40 Hz, 2 H) 4.24 - 4.34 (m, 1 H) 5.61 (dd, J=7.40, 4.14 Hz, 1 H) 7.51 (d, J=7.60 Hz, 1 H) 7.53 (br. s, 2 H) 7.84 (s, 1 H) 8.17 (d, J=8.78 Hz, 1 H) 8.44 (d, J=5.52 Hz, 1 H) 11.77 (br. s., 1 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.82 (t, J=7.40 Hz, 3 H) 1.11 - 1.22 (m, 2 H) 1.43 - 1.55 (m, 2 H) 1.66 - 1.76 (m, 2 H) 2.25 - 2.34 (m, 1 H) 2.52 - 2.65 (m, 1 H) 2.88

284 - 2.97 (m, 1 H) 3.10 - 3.22 (m, 1

377.16 378 0.92, D

H) 3.43 (t, J=6.40 Hz, 2 H) 4.24 - 4.34 (m, 1 H) 5.61 (dd, J=7.40, 4.14 Hz, 1 H) 7.51 (d, J=7.60 Hz, 1 H) 7.53 (br. s, 2 H) 7.84 (s, 1 H) 8.17 (d, J=8.78 Hz, 1 H) 8.44 (d, J=5.52 Hz, 1 H) 11.77 (br. s., 1 H) Η NMR (400 MHz, DMSO-d ₆ ) δ ppm 0.62 - 0.92 (m, 3 H) 1.14 - 1.31 (m, 2 H) 1.42 - 1.63 (m, 2 H) 1.63 - 1.82 (m, 2 H) 3.40 (t,

285 J=6.40 Hz, 2 H) 4.25 - 4.36 (m, 1

383.21 384 0.8, D

H) 5.22 (s, 2 H) 7.47 - 7.59 (m, 1

A- H) 7.47 - 7.59 (m, 2 H) 7.59 - 7.67

(m, 2 H) 7.72 (br. s., 1 H) 7.85 - 7.98 (m, 2 H) 8.08 (d, J=8.78 Hz, 1 H) 9.07 (s, 1 H) 12.16 (br. s., 1 H)

Analytical Methods.

All compounds were characterized by LC-MS. The following LC-MS methods were used:

Method A. Waters Aquity UPLC equipped with a PDA detector (210-400 nm) and a Waters SQD with a dual mode ion source ES+/-. The column used was a Halo C18, 2.7 μηπ, 2.1 x 50 mm, heated to 50°C. A gradient of 95% aqueous formic acid (0.1 %)/5% acetonitnle to 100% acetonitrile was ramped over 1 .5 minutes, held for 0.6 minutes, then returns to 100% aqueous formic acid (0.1 %) for 0.5 minutes. The flow rate was 0.6 mL/min. Method B.

Method C.

Method D. Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C18 column (1 .7 μηι, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min. Two mobile phases (10 mM ammonium acetate in H ₂ 0/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1 .3 minutes and hold for 0.7 minutes. An injection volume of 0.75 μΙ was used. Cone voltage was 30 V for positive ionization mode and 30 V for negative ionization mode. Method E. Using a Phenomenex Kinetex column(XB-C18 50 x 4.6 mm I.D. 2.6u) held at 35°C. MS detection: API-ES Positive ionization mode, Mass range 100-1200. PDA detection (A=190-400nm). The following gradient was used with a 2μΙ_ injection:

Method F. Using a YMC ODS-AQ C-18;50 x 4.6 mm, ID = 3μηπ held at 35°C. MS detection: API-ES Positive ionization mode, Mass range 100-1400. PDA detection (A=190-400nm). The following gradient was used with a 2μΙ_ injection:

Solvent A H ₂ 0 + 0.1 % Formic Acid

Solvent B Acetonitrile

Time (min) %A %B Flow (ml/min)

0.0 95 5 2.6

4.8 5 95 2.6

5.8 5 95 2.6

6.0 95 5 2.6 Method G. Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40 °C). Flow from the column was split to a MS spectrometer. The MS detector was configured with an electrospray ionization source. The capillary needle voltage was 3 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas. Xterra MS C18 column (3.5 pm, 4.6 x 100 mm) with a flow rate of 1 .6 mL/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50 % B and 50 % C in 6.5 minutes, to 100 % B in 0.5 minute, 100 % B for 1 minute and re-equilibrate with 100 % A for 1 .5 minutes. An injection volume of 10 μΙ was used.

Method H. Reversed phase UPLC (Ultra Performance Liquid Chromato- graphy) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C18 column (1 .7 pm, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 mL/min. Two mobile phases (mobile phase A: 10mM ammonium acetate in H ₂ 0/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1 .3 minutes and hold for 0.2 minutes. An injection volume of 0.5 μΙ was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.

Biological Activity of compounds of formula (I)

Description of Biological Assays Assessment of TLR7 and TLR8 activity

The ability of compounds to activate human TLR7 and/or TLR8 was assessed in a cellular reporter assay using HEK293 cells transiently transfected with a TLR7 or TLR8 expression vector and NFKB-IUC reporter construct. In one instance the TLR expression construct expresses the respective wild type sequence or a mutant sequence comprising a deletion in the second leucine- rich repeat of the TLR. Such mutant TLR proteins have previously been shown to be more susceptible to agonist activation (US 7498409).

Briefly, HEK293 cells were grown in culture medium (DMEM supplemented with 10% FCS and 2 mM Glutamine). For transfection of cells in 10 cm dishes, cells were detached with Trypsin-EDTA, transfected with a mix of CMV-TLR7 or TLR8 plasmid (750 ng), N FKB-IUC plasmid (375 ng) and a transfection reagent and incubated for 48 hours at 37°C in a humidified 5% CO2 atmosphere. Transfected cells were then detached with Trypsin-EDTA, washed in PBS and resuspended in medium to a density of 1 .67 x 10 ⁵ cells/mL. Thirty microliters of cells were then dispensed into each well in 384-well plates, where 10 μί of compound in 4% DMSO was already present. Following 6 hours incubation at 37°C, 5% CO2, the luciferase activity was determined by adding 15 μΙ of Steady Lite Plus substrate (Perkin Elmer) to each well and readout performed on a ViewLux ultraHTS microplate imager (Perkin Elmer). Dose response curves were generated from measurements performed in quadruplicates. Lowest effective concentrations (LEC) values, defined as the concentration that induces an effect which is at least two fold above the standard deviation of the assay, were determined for each compound.

Compound toxicity was determined in parallel using a similar dilution series of compound with 30 μί per well of cells transfected with the CMV-TLR7 construct alone (1.67 x 10 ⁵ cells/mL), in 384-well plates. Cell viability was measured after 6 hours incubation at 37°C, 5% CO2 by adding 15 μί of ATP lite (Perkin Elmer) per well and reading on a ViewLux ultraHTS microplate imager (Perkin Elmer). Data was reported as CC50. Suppression of HCV replicon replication

Activation of human TLR7 results in robust production of interferon by plasmacytoid dendritic cells present in human blood. The potential of compounds to induce interferon was evaluated by looking at the antiviral activity in the HCV replicon system upon incubation with conditioned media from peripheral blood mononuclear cells (PBMC). The HCV replicon assay is based on a bicistronic expression construct, as described by Lohmann et al. (Science (1999) 285: 1 10-1 13; Journal of Virology (2003) 77: 3007-15 3019) with modifications described by Krieger et al. (Journal of Virology (2001 ) 75: 4614-4624). The assay utilized the stably transfected cell line Huh-7 luc/neo harboring an RNA encoding a bicistronic expression construct comprising the wild type NS3-NS5B regions of HCV type 1 b translated from an Internal Ribosome Entry Site (IRES) from encephalomyocarditis virus (EMCV), preceded by a reporter gene (Firefly-luciferase) and a selectable marker gene (neoR, neomycine phosphotransferase). The construct is flanked by 5' and 3' NTRs (non-translated regions) from HCV type 1 b. Continued culture of the replicon cells in the presence of G418 (neoR) is dependent on the replication of the HCV RNA. The stably transfected replicon cells that replicate HCV RNA autonomously and to high levels, encoding inter alia luciferase, were used for profiling of the conditioned cell culture media.

Briefly, PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll centrifugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 10 ⁵ cells/well were dispensed into 384-well plates containing compounds (70 μΙ_ total volume). After overnight incubation, 10 μί of supernatant was transferred to 384-well plates containing 2.2 x 10 ³ replicon cells/well in 30 μΙ_ (plated the day before). Following 24 hours of incubation, replication was measured by assaying luciferase activity using 40 L/well Steady Lite Plus substrate (Perkin Elmer) and measured with ViewLux ultraHTS microplate imager (Perkin Elmer). The inhibitory activity of each compound on the Huh7-luc/neo cells were reported as EC50 values, defined as the compound concentration applied to the PBMCs resulting in a 50% reduction of luciferase activity which in turn indicates the degree of replication of the replicon RNA on transfer of a defined amount of PBMC culture medium. Recombinant interferon a-2a (Roferon-A) was used as a standard control compound.

Biological activity of compounds of formula (I) . All compounds showed CC50 of >24uM in the HEK 293 TOX assay described above.

Activation of ISRE promoter elements

The potential of compounds to induce IFN-I was also evaluated by measuring the activation of interferon-stimulated responsive elements (ISRE) by conditioned media from PBMC. The ISRE element of sequence GAAACTGAAACT is highly responsive to the STAT1 -STAT2-IRF9 transcription factor, activated upon binding of IFN-I to their receptor IFNAR (Clontech, PT3372-5W). The plasmid pISRE-Luc from Clontech (ref. 631913) contains 5 copies of this ISRE element, followed by the firefly luciferase ORF. A HEK293 cell line stably transfected with pISRE-Luc (HEK-ISREluc) was established to profile of the conditioned PBMC cell culture media.

Briefly, PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll centrifugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 10 ⁵ cells/well were dispensed into 384-well plates containing compounds (70 μΙ_ total volume). After overnight incubation, 10 μί of supernatant was transferred to 384-well plates containing 5 x 10 ³ HEK-ISREluc cells/well in 30 μί (plated the day before). Following 24 hours of incubation, activation of the ISRE elements was measured by assaying luciferase activity using 40 L/well Steady Lite Plus substrate (Perkin Elmer) and measured with ViewLux ultraHTS microplate imager (Perkin Elmer). The stimulating activity of each compound on the HEK- ISREluc cells was reported as LEC value, defined as the compound concentration applied to the PBMCs resulting in a luciferase activity at least two fold above the standard deviation of the assay. The LEC in turn indicates the degree of ISRE activation on transfer of a defined amount of PBMC culture medium. Recombinant interferon a-2a (Roferon-A) was used as a standard control compound.

For a given compound, the LEC value obtained from this assay were in the same range as the EC50 values obtained from the "suppression of HCV replication assay." Thus, it is possible to compare the potential of compounds to induce IFN-I by PBMC, measured by either of the 2 assays.

TABLE II BIOLOGICAL ACTIVITY OF THE COMPOUNDS.

PBMC HEK-

TLR7 TLR8

HUH-7 ISREluc

Structure wt LEC wt LEC

EC ₅₀ LEC

"A 0.713 1.720 0.157 ND

ND = Not done.